View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 09, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Trading Symbol	BBIO
Entity Registrant Name	BridgeBio Pharma, Inc.
Entity Central Index Key	0001743881
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	No
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity File Number	001-38959
Entity Tax Identification Number	841850815
Entity Address, Address Line One	421 Kipling Street
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94301
City Area Code	650
Local Phone Number	391-9740
Entity Common Stock, Shares Outstanding		116,755,512

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	May 17, 2019
Liabilities
Commitments and contingencies
Stockholders’ Deficit
Undesignated preferred stock, $0.001 par value; 25,000,000 and no shares authorized as of June 30, 2019 and May 17, 2019; no shares issued and outstanding as of June 30, 2019 and May 17, 2019
Common stock, $0.001 par value; 500,000,000 and 1,000 shares authorized as of June 30, 2019 and May 17, 2019; no shares issued and outstanding as of June 30, 2019 and May 17, 2019	0	$ 0
Additional paid-in capital	69
Accumulated deficit	$ (69)

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2019	Jun. 26, 2019	May 17, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000	0
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000	1,000
Common stock, shares issued	0		0
Common stock, shares outstanding	0		0

Condensed Statements of Operations and Comprehensive Loss (Unaudited) $ in Thousands	1 Months Ended
	Jun. 30, 2019 USD ($)
Operating expenses:
General and administrative	$ 69
Total operating expenses	69
Net loss and comprehensive loss	$ (69)

Condensed Statement of Changes in Stockholders' Deficit (Unaudited) - 1 months ended Jun. 30, 2019 - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance at May. 17, 2019	$ 0	$ 0	$ 0	$ 0
Stock-based compensation	69	0	69	0
Net loss	(69)	0	0	(69)
Ending balance at Jun. 30, 2019	$ 0	$ 0	$ 69	$ (69)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 112,400	$ 238,700
Current liabilities:
Commitments and contingencies
Members’ deficit:
Accumulated deficit	(69)
BridgeBio Pharma LLC
Current assets:
Cash and cash equivalents	293,803	436,086
Prepaid expenses and other current assets	12,906	9,137
Total current assets	306,709	445,223
Property and equipment, net	1,865	1,575
PellePharm investment	7,495	17,050
Other assets	9,471	1,093
Total assets	325,540	464,941
Current liabilities:
Accounts payable	16,065	13,509
Accrued compensation and benefits	4,736	4,047
Accrued research and development liabilities	9,419	8,915
Accrued distributions to unitholders		997
LEO call option liability	4,297	3,009
Other accrued liabilities	4,188	2,100
Total current liabilities	38,705	32,577
Term loans, noncurrent	74,997	54,507
Other liabilities	347	495
Total liabilities	114,049	87,579
Commitments and contingencies
Members’ deficit:
Accumulated deficit	(326,068)	(170,580)
Total BridgeBio members’ deficit	(326,068)	(170,580)
Noncontrolling interests	48,391	62,361
Total members’ deficit	(277,677)	(108,219)
Total liabilities and stockholders’ deficit	325,540	464,941
BridgeBio Pharma LLC \| Redeemable Convertible Preferred Units
Current liabilities:
Temporary equity	479,044	478,865
BridgeBio Pharma LLC \| Redeemable Founder Units
Current liabilities:
Temporary equity	1,754	1,754
BridgeBio Pharma LLC \| Redeemable Common Units
Current liabilities:
Temporary equity	1,672	1,619
BridgeBio Pharma LLC \| Management Incentive Units
Current liabilities:
Temporary equity	6,523	3,221
BridgeBio Pharma LLC \| Redeemable Convertible Noncontrolling Interests
Current liabilities:
Temporary equity	$ 175	$ 122

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
BridgeBio Pharma LLC
Operating expenses:
Research and development	$ 52,331	$ 23,892	$ 97,184	$ 57,723
General and administrative	16,918	10,891	35,817	18,898
Total operating expenses	69,249	34,783	133,001	76,621
Loss from operations	(69,249)	(34,783)	(133,001)	(76,621)
Other income (expense), net:
Interest income	1,662	2	3,769	3
Interest expense	(1,941)	(205)	(3,612)	(212)
Loss from PellePharm	(4,956)		(9,555)
LEO call option income (expense)	226		(1,288)
Other income (expense)	(7)	(716)	(14)	(1,302)
Total other income (expense), net	(5,016)	(919)	(10,700)	(1,511)
Net loss and comprehensive loss	(74,265)	(35,702)	(143,701)	(78,132)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	8,370	9,151	16,621	17,425
Net loss and comprehensive loss attributable to BridgeBio	(65,895)	(26,551)	(127,080)	(60,707)
Cumulative returns on redeemable convertible preferred units (Series A, Series B and Series C)		(3,854)		(6,975)
Net loss attributable to redeemable founder units and redeemable common units	$ (65,895)	$ (30,405)	$ (127,080)	$ (67,682)
Net loss per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted	$ (3.46)	$ (1.71)	$ (6.69)	$ (3.83)
Total weighted-average redeemable founder units and redeemable common units used in computing net loss per unit, basic and diluted	19,033,838	17,821,117	18,995,957	17,654,249

Condensed Consolidated Statements of Redeemable Convertible Preferred, Redeemable Founder, Common, Management Incentive Units, Convertible Noncontrolling Interests and Members' Deficit Equity - BridgeBio Pharma LLC - USD ($) $ in Thousands	Total	Accumulated Deficit	Noncontrolling Interests	Redeemable Convertible Preferred Units	Redeemable Founder Units	Redeemable Common Units	Management Incentive Units	Redeemable Convertible Noncontrolling Interests
Temporary equity, beginning balance at Dec. 31, 2017				$ 143,867	$ 1,754	$ 1,431	$ 226	$ 833
Temporary equity, beginning balance, units at Dec. 31, 2017				219,406,923	11,420,741	5,856,075	9,835,925
Issuance and vesting of associated with equity-based compensation						$ 47	$ 275
Issuance and vesting of associated with equity-based compensation, units						335,427	2,275,572
Issuance (repurchase) of noncontrolling interest								15,617
Transfers to (from) noncontrolling interest								(11,286)
Net loss and comprehensive loss	$ (38,816)	$ (34,156)	$ (4,660)					(3,614)
Temporary equity, ending balance at Mar. 31, 2018				$ 143,867	$ 1,754	$ 1,478	$ 501	1,550
Temporary equity, ending balance, units at Mar. 31, 2018				219,406,923	11,420,741	6,191,502	12,111,497
Beginning balance at Dec. 31, 2017	(58,929)	(61,427)	2,498
Issuance (repurchase) of noncontrolling interest	553		553
Transfers to (from) noncontrolling interest	11,286	3,876	7,410
Ending balance at Mar. 31, 2018	(85,906)	(91,707)	5,801
Issuance and vesting of associated with equity-based compensation						$ 48	$ 277
Issuance and vesting of associated with equity-based compensation, units						335,427	2,283,905
Issuance of Series C redeemable convertible preferred units				$ 36,300
Issuance of redeemable convertible preferred units, Shares				37,593,206
Issuance (repurchase) of noncontrolling interest								46,710
Transfers to (from) noncontrolling interest								(41,450)
Net loss and comprehensive loss	(32,084)	(26,551)	(5,533)					(3,618)
Temporary equity, ending balance at Jun. 30, 2018				$ 180,167	$ 1,754	$ 1,526	$ 778	3,192
Temporary equity, ending balance, units at Jun. 30, 2018				257,000,129	11,420,741	6,526,929	14,395,402
Issuance (repurchase) of noncontrolling interest	96,689		96,689
Transfers to (from) noncontrolling interest	41,450	56,182	(14,732)
Ending balance at Jun. 30, 2018	20,149	(62,076)	82,225
Temporary equity, beginning balance at Dec. 31, 2018				$ 478,865	$ 1,754	$ 1,619	$ 3,221	122
Temporary equity, beginning balance, units at Dec. 31, 2018				407,955,726	11,420,741	7,197,783	19,117,628
Issuance and vesting of associated with equity-based compensation						$ 26	$ 1,210
Issuance and vesting of associated with equity-based compensation, units						335,427	2,831,171
Repayment of nonrecourse notes				$ 179
Transfers to (from) noncontrolling interest								870
Net loss and comprehensive loss	(68,646)	(61,185)	(7,461)					(790)
Temporary equity, ending balance at Mar. 31, 2019				$ 479,044	$ 1,754	$ 1,645	$ 4,431	202
Temporary equity, ending balance, units at Mar. 31, 2019				407,955,726	11,420,741	7,533,210	21,948,799
Beginning balance at Dec. 31, 2018	(108,219)	(170,580)	62,361
Issuance (repurchase) of noncontrolling interest	1,320		1,320
Transfers to (from) noncontrolling interest	(870)	(2,968)	2,098
Ending balance at Mar. 31, 2019	(176,415)	(234,733)	58,318
Issuance and vesting of associated with equity-based compensation						$ 27	$ 2,092
Issuance and vesting of associated with equity-based compensation, units						335,427	3,629,209
Transfers to (from) noncontrolling interest								658
Net loss and comprehensive loss	(73,580)	(65,895)	(7,685)					(685)
Temporary equity, ending balance at Jun. 30, 2019				$ 479,044	$ 1,754	$ 1,672	$ 6,523	$ 175
Temporary equity, ending balance, units at Jun. 30, 2019				407,955,726	11,420,741	7,868,637	25,578,008
Issuance (repurchase) of noncontrolling interest	(27,024)		(27,024)
Transfers to (from) noncontrolling interest	(658)	(25,440)	24,782
Ending balance at Jun. 30, 2019	$ (277,677)	$ (326,068)	$ 48,391

Condensed Consolidated Statements of Redeemable Convertible Preferred, Redeemable Founder, Common, Management Incentive Units, Convertible Noncontrolling Interests and Members' Deficit Equity (Parenthetical) - BridgeBio Pharma LLC - Series C Redeemable Convertible Preferred Units $ in Thousands	3 Months Ended
	Jun. 30, 2018 USD ($) $ / shares
Issuance of redeemable convertible preferred stock per share \| $ / shares	$ 0.9656
Issuance costs \| $	$ 0

Condensed Consolidated Statements of Cash Flows (Unaudited) - BridgeBio Pharma LLC - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Operating activities:
Net loss	$ (143,701)	$ (78,132)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	244	68
Equity-based compensation	5,521	1,768
Loss on disposal of property and equipment, net	8	7
Loss from PellePharm	9,555
Accretion of term loans and convertible promissory notes	702	264
Acquired in-process research and development assets	2,500	17,886
Shares issued under license agreements	220	134
LEO call option expense	1,288
Change in fair value of Eidos financial instruments		1,146
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(3,345)	(8,118)
Other assets	(2,077)	133
Accounts payable	146	8,856
Accrued compensation and benefits	689	588
Accrued research and development liabilities	505	3,097
Other accrued liabilities	505	273
Other liabilities	(148)	123
Net cash used in operating activities	(127,388)	(51,907)
Investing activities
Cash paid for in-process research and development assets acquired	(2,500)	(16,000)
Purchases of property and equipment	(510)	(832)
Net cash used in investing activities	(3,010)	(16,832)
Financing activities
Proceeds from the issuance of Series C preferred units, net of issuance costs		36,300
Proceeds from issuance of common stock in connection with the initial public offering of Eidos, net of underwriting discounts and commissions		96,723
Proceeds from issuance of promissory notes		1,000
Proceeds from repayment of nonrecourse notes	179
Proceeds from term loans, net of issuance costs	19,787	36,590
Proceeds from third-party investors in redeemable convertible noncontrolling interests		58,430
MyoKardia distributions (Note 13)	(997)
Repurchase of noncontrolling interest	(28,628)
Proceeds from repayment of the loans received by noncontrolling interest shareholder		(17)
Payment of deferred offering costs	(2,499)
Proceeds from subsidiary stock option exercises	538	75
Net cash provided by (used in) financing activities	(11,620)	229,101
Net increase (decrease) in cash, cash equivalents and restricted cash	(142,018)	160,362
Cash, cash equivalents and restricted cash at beginning of period	436,245	92,376
Cash, cash equivalents and restricted cash at end of period	294,227	252,738
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	2,583	19
Supplemental Disclosures of Non-Cash Investing and Financing Information:
Transfers to (from) noncontrolling interest (Note 6)	28,408	60,058
Deferred offering costs included in accounts payable and other accrued liabilities	$ 3,961	1,187
Conversion of redeemable noncontrolling interest into noncontrolling interest		12,252
Conversion of promissory note into redeemable convertible noncontrolling interest		1,005
Fair value of redeemable convertible noncontrolling interest issued for acquired in-process research and development assets		$ 1,886

Organization and Background

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization and Background

1.	Organization and Background

BridgeBio Pharma, Inc. (the “Corporation”) was formed as a Delaware corporation on May 17, 2019. The Corporation was formed for the purpose of completing an initial public offering of the Corporation’s common stock (the “IPO”) and related transactions in order to carry on the business of BridgeBio Pharma LLC (the “Reorganization”). From incorporation through June 30, 2019, the Corporation did not have any shares of common stock outstanding. Accordingly, basic and diluted net loss attributable to common stockholders has not been presented.

Upon the closing of the IPO on July 1, 2019, all unitholders of BridgeBio Pharma LLC exchanged their units for shares of common stock of the Corporation, and BridgeBio Pharma LLC became a wholly-owned subsidiary of the Corporation as part of the Reorganization. As the sole managing member, the Corporation will operate and control all of BridgeBio Pharma LLC’s businesses and affairs after the Reorganization. As of June 30, 2019, these condensed financial statements, including share and per share amounts, do not give effect to the Reorganization or the IPO as these transactions were completed subsequent to June 30, 2019. Refer to Note 5 for additional information.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2019

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation

The unaudited condensed balance sheets, condensed statement of operations and comprehensive loss and condensed statement of changes in stockholders’ deficit are presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). A statement of cash flows has not been presented because there have been no cash activities in this entity from inception on May 17, 2019 and through June 30, 2019.

The unaudited condensed financial statements have been prepared on the same basis that would be applied to the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Corporation’s financial position as of June 30, 2019 and the results of operations and comprehensive loss from inception on May 17, 2019 and through June 30, 2019. The results of operations for the period from May 17, 2019 through June 30, 2019 are not necessarily indicative of the results to be expected for the period from May 17, 2019 through December 31, 2019 or for any other future annual or interim period.

Underwriting Commissions and Offering Costs

Underwriting commissions and offering costs incurred in connection with the Corporation’s offering of its common stock will be reflected as a reduction of additional paid-in capital subsequent to June 30, 2019. Underwriting commissions and offering costs are not recorded in the Corporation’s balance sheet because such costs did not become the Corporation’s liability until the Corporation completed the Reorganization and the IPO subsequent to June 30, 2019.

Organizational Costs

Organizational costs are not recorded in the Corporation’s balance sheet as of June 30, 2019 because such costs are not the Corporation’s liability until the Corporation completes the Reorganization and the IPO. Thereafter, costs incurred to organize the Corporation will be expensed as incurred.

Equity-Based Compensation

Equity-based compensation is measured at the grant date for all equity-based awards made to employees and non-employees based on the fair value of the awards and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Corporation has elected to recognize the actual forfeitures by reducing the equity-based compensation in the same period as the forfeitures occur. The description of fair value measurement method for the awards is presented in Note 4. The Corporation granted stock options to employees and non-employees of BridgeBio Pharma LLC and its affiliates. These awards generally have only a service condition and vest over a period of four years. The Corporation classifies equity-based compensation in its unaudited statement of operations in the same manner in which the award recipients’ payroll costs or the award recipients’ service payments would be classified, if any were made during the reporting period.

BridgeBio Pharma LLC

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and applicable rules and regulations of SEC regarding interim financial reporting.

The interim condensed consolidated balance sheet as of June 30, 2019, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2019 and 2018, the condensed consolidated statements of redeemable convertible preferred units, redeemable founder units, redeemable common units, management incentive units, redeemable convertible noncontrolling interests and members’ deficit for the three and six months ended June 30, 2019 and 2018 and the statements of cash flows for the six months ended June 30, 2019 and 2018 are unaudited.

The condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, its results of operations and comprehensive loss, and its cash flows for the periods presented. The financial data and the other financial information contained in these notes to the condensed consolidated financial statements related to the three and six-month periods are also unaudited. The results of operations for the three and six months ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements included in the prospectus dated June 26, 2019 (“Prospectus”) that forms a part of the Company's Registration Statements on Form S-1 (File Nos. 333-231759 and 333-232376), as filed with the SEC pursuant to Rule 424(b)(4) promulgated under the Securities Act of 1933, as amended.

Variable Interest Entities and Voting Interest Entities

BridgeBio consolidates those entities in which it has a direct or indirect controlling financial interest based on either the Variable Interest Entity (“VIE”) model or the Voting Interest Entity (“VOE”) model.

At the VIE’s inception, BridgeBio determines whether it is the primary beneficiary and if the VIE should be consolidated based on the facts and circumstances. BridgeBio then performs on-going reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation conclusion is required each reporting period. Refer to Note 5.

Entities that do not qualify as a VIE are assessed for consolidation under the VOE model. Under the VOE model, BridgeBio consolidates the entity if it determines that it, directly or indirectly, has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. Refer to Note 5.

BridgeBio has either created or made investments in the following entities:

Consolidated Entities	Relationship as of June 30, 2019	Date Control First Acquired	Ownership % as of June 30, 2019			Ownership % as of December 31, 2018
			(unaudited)
TheRas, Inc.	Wholly-owned subsidiary	August 2016		100	%		100	%
BridgeBio Services, Inc.	Wholly-owned subsidiary	April 2017		100	%		100	%
Fortify Therapeutics, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Sub20, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Unnamed Entity #1	Wholly-owned subsidiary	December 2018		100	%		100	%
Unnamed Entity #2	Wholly-owned subsidiary	April 2019		100	%		—
Unnamed Entity #3	Wholly-owned subsidiary	May 2019		100	%		—
Eidos Therapeutics, Inc.⁽¹⁾	Partially-owned subsidiary	April 2016		65.1	%		62.5	%
Molecular Skin Therapeutics, Inc.	Controlled VIE	July 2016		58.2	%		61.7	%
Quartz Therapeutics, Inc.	Controlled VIE	October 2016		89.0	%		89.0	%
PellePharm, Inc.⁽²⁾	VIE	December 2016		43.3	%		43.3	%
Navire Pharma, Inc.	Controlled VIE	February 2017		78.9	%		78.8	%
CoA Therapeutics, Inc.	Controlled VIE	February 2017		99.6	%		99.5	%
Dermecular Therapeutics, Inc.	Controlled VIE	April 2017		87.6	%		87.6	%
Phoenix Tissue Repair, Inc.	Controlled VIE	July 2017		56.4	%		56.7	%
QED Therapeutics, Inc.	Controlled VIE	January 2018		96.6	%		94.4	%
Adrenas Therapeutics, Inc.	Controlled VIE	January 2018		88.7	%		90.1	%
Orfan Biotech, Inc.	Controlled VIE	January 2018		89.6	%		85.1	%
Ferro Therapeutics, Inc.	Controlled VIE	March 2018		90.0	%		89.4	%
Origin Biosciences, Inc.	Controlled VIE	April 2018		99.8	%		100	%
Venthera, Inc.	Controlled VIE	April 2018		81.8	%		82.0	%
Aspa Therapeutics, Inc.	Controlled VIE	June 2018		90.3	%		92.5	%

(1)	Subsequent to the Eidos Therapeutics, Inc. (“Eidos”) initial public offering in June 2018 and through June 30, 2019, BridgeBio has a majority voting interest in Eidos and consolidates Eidos under the VOE model. Refer to Note 5.

(2)

Subsequent to the execution of a series of agreements (the “LEO Agreement”) with LEO Pharma A/S and LEO Spiny Merger Sub, Inc. (“LEO”) in November 2018, BridgeBio determined that it is no longer the primary beneficiary of PellePharm, Inc. (“PellePharm”) and deconsolidated PellePharm. Refer to Note 7.

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to, the fair value of the Preferred Units, the fair value of the Founder Units, the fair value of the LEO Call Option liability, the valuation of equity-based awards, income tax uncertainties and accruals for research and development activities. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.

Cash, Cash Equivalents and Restricted Cash

As of June 30, 2019 and December 31, 2018, the Company had restricted cash of $0.4 million and $0.2 million. Restricted cash is classified in prepaid expenses and other current assets and other assets in the accompanying condensed consolidated balance sheets as of June 30, 2019 and December 31, 2018, respectively.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the amounts shown in the condensed consolidated statements of cash flows:

	June 30, 2019		June 30, 2018
	(in thousands)
Cash and cash equivalents	$	293,803	$	252,379
Restricted cash		424		359
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	294,227	$	252,738

As of June 30, 2019 and December 31, 2018, total cash and cash equivalents held by BridgeBio was $112.4 million and $238.7 million. The remaining cash and cash equivalents were held by the Company’s wholly-owned subsidiaries and controlled entities and these funds are designated for specific entity usage, except in limited circumstances.

Fair Value Measurements

Assets and liabilities recorded at fair value on a recurring basis in the balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

The fair value of the Company’s outstanding term loans with Hercules Capital, Inc. (see Note 9) is estimated using the net present value of the payments, discounted at an interest rate that is consistent with a market interest rate, which is a Level 2 input. The estimated fair value of the Company’s outstanding term loans approximates the carrying amount, as the term loan bears a floating rate that approximates the market interest rate.

Deferred Offering Costs

The Company has deferred offering costs, consisting of legal, accounting, printer and filing fees related to the IPO, that were deferred and were offset against the offering proceeds upon the completion of the IPO on July 1, 2019. As of June 30, 2019, $6.5 million of deferred offering costs were recorded within other assets on the condensed consolidated balance sheet. As of December 31, 2018, no amounts were deferred.

Net Loss per Unit

The holders of the Company’s Preferred Units are entitled to receive distributions, including cumulative returns on their units outstanding, prior and in preference to any distributions on any of the Company’s Founder Units and Common Units, which are also entitled to cumulative returns. Cumulative returns for Preferred Units, Common Units and Founder Units no longer accumulate subsequent to the Series D Preferred Unit financing in November 2018. For the three and six months ended June 30, 2019 and 2018, the Company determined that its Founder Units and Common Units are common stock equivalents.

Basic net loss per unit is the same as diluted net loss per unit as the inclusion of all potentially dilutive. Preferred Units, unvested Common Units, and Management Incentive Units would have been anti-dilutive.

Recently Adopted Accounting Pronouncements

ASU 2015-17 Income Taxes (Topic 740). In November 2015, the FASB issued ASU 2015-17 Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes (“ASU 2015-17”), which simplifies the presentation of deferred taxes in a classified balance sheet by eliminating the requirement to separate deferred income tax liabilities and assets into current and noncurrent amounts. Instead, ASU 2015-17 requires that all deferred tax liabilities and assets be shown as noncurrent in a classified balance sheet. ASU 2015-17 is effective for fiscal years beginning after December 15, 2017 and may be applied either prospectively or retrospectively to all periods presented. The Company adopted this guidance on January 1, 2018. The condensed consolidated balance sheets as of June 30, 2019 and December 31, 2018 are presented in accordance with this guidance.

Recently Issued Accounting Pronouncements Not Yet Adopted

ASU 2016-02 Leases (Topic 842). In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which for operating leases requires the lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The guidance also requires a lessee to recognize single lease costs, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, including a number of optional practical expedients that entities may elect to apply. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the appropriate transition method and impact of this guidance on its consolidated financial statements and related disclosures.

ASU 2016-15 Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). The areas affected by ASU 2016-15 are debt prepayment and debt extinguishment costs, settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies (including bank-owned life insurance policies), distributions received from equity method investees, beneficial interests in securitization transactions and separately identifiable cash flows and application of the predominance principle. Specifically, under this guidance, cash payments for debt prepayment or debt extinguishment costs will be classified as cash outflows for financing activities. The amendments in ASU 2016-15 are effective for fiscal years beginning after December 15, 2018 and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. The amendments in ASU 2016-15 will be applied using a retrospective transition method to each period presented. The adoption of ASU 2016-15 is not expected to materially impact the Company’s consolidated financial statements.

ASU 2018-13, Fair Value Measurement – Disclosure Framework (Topic 820). In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement - Disclosure Framework (Topic 820) (“ASU 2018-13”). The updated guidance improves the disclosure requirements on fair value measurements and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted upon issuance of the standard for disclosures modified or removed with a delay of adoption of the additional disclosures until their effective date. The adoption of ASU 2018-13 is not expected to materially impact the Company’s consolidated financial statements.

Stockholders' Deficit

6 Months Ended

Jun. 30, 2019

Equity [Abstract]

Stockholders' Deficit

3.	Stockholders’ Deficit

On May 17, 2019, the Corporation was authorized to issue 1,000 shares of common stock, par value $0.001 per share.

On June 26, 2019, the Corporation amended and restated its certificate of incorporation to increase the authorized capital stock to 500,000,000 shares of common stock with a par value of $0.001 and to 25,000,000 shares of undesignated preferred stock with a par value of $0.001.

No shares of common stock or preferred stock had been issued or are outstanding as of June 30, 2019.

Stock-based Compensation

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock/Equity-based Compensation

4.	Stock-based Compensation

2019 Stock Option and Incentive Plan

On June 22, 2019, the Corporation adopted the 2019 Stock Option and Incentive Plan (the “2019 Plan”), which became effective on June 25, 2019. The 2019 Plan provides for the grant of equity-based incentive awards. The Corporation initially reserved 11,500,000 shares of common stock for issuance of awards under the 2019 Plan. The 2019 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31, or such lesser number of shares as determined by the Compensation Committee of the Board of Directors.

On June 21, 2019, the Board of Directors approved the grant of options to purchase 3,696,429 shares of common stock to certain employees and non-employees of BridgeBio Pharma LLC and its affiliates at an exercise price equal to the IPO price of its common stock, which was $17.00 per share. On June 26, 2019, the Board of Directors approved the grant of options to purchase an additional 48,200 shares of common stock to certain employees and non-employees of BridgeBio Pharma LLC and its affiliates at the same exercise price. The options granted have a service condition and vest over a period of four years. All expenses included in the Corporation’s statement of operations represent recorded stock-based compensation in relation to these June 2019 grants.

The following table summarizes the Corporation’s stock option activity for the period from May 17, 2019 through June 30, 2019:

	Options Available for Grant			Options Outstanding		Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of May 17, 2019		—			—	$	—		—	$	—
Authorized		11,500,000			—	$	—
Granted		(3,744,629	)		3,744,629	$	17.00
Outstanding as of June 30, 2019		7,755,371			3,744,629	$	17.00		6.02	$	37,334
Exercisable as of June 30, 2019					—	$	—		—	$	—

Determination of Fair Value

The fair value of each stock option grant was determined by the Corporation at the grant date using a Black-Scholes option-pricing model with the following assumptions:

	May 17, 2019 – June 30, 2019
Expected term (in years)	6.02-6.08
Expected volatility		37.5	%
Risk-free interest rate		1.86	%
Dividend yield		—
Weighted average fair value of share-based awards granted	$	6.64

As of June 30, 2019, there was $24.8 million of total unrecognized compensation cost related to unvested equity-based compensation arrangements under the 2019 Plan. The unrecognized equity-based compensation cost is expected to be recognized over a weighted-average period of 4.0 years.

2019 Employee Stock Purchase Plan

On June 22, 2019, the Corporation adopted the 2019 Employee Stock Purchase Plan (the “ESPP”) which became effective on June 25, 2019. The ESPP initially reserves and authorizes the issuance of up to a total of 2,000,000 shares of common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2020, by the lower of: i) 1% of the outstanding number of shares of common stock on the immediately preceding December 31, ii) 2,000,000 shares or iii) such lesser number of shares as determined by the Compensation Committee.

As of June 30, 2019, no shares were issued and outstanding under the ESPP.

Subsequent Events

6 Months Ended

Jun. 30, 2019

Subsequent Events

5.	Subsequent Events

Initial Public Offering

On July 1, 2019, the Corporation closed the IPO of its common stock. As part of the IPO, the Corporation issued and sold 23,575,000 shares of its common stock, which included 3,075,000 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $17.00 per share. The Corporation received net proceeds of approximately $366.3 million from the IPO, after deducting underwriters’ discounts and commissions of $28.0 million and offering costs of $6.5 million.

Reorganization

On June 13, 2019, the Corporation formed BridgeBio Pharma Merger Sub LLC (“Merger Sub LLC”), a Delaware limited liability company and direct wholly-owned subsidiary.

On July 1, 2019, upon execution of the Reorganization, all outstanding units of BridgeBio Pharma, LLC were cancelled and exchanged for shares of common stock of the Corporation, as shown in the below table by unit class:

BridgeBio Pharma, LLC unit class	Number of BridgeBio Pharma, Inc. Shares Issued
Series D Preferred Units		30,459,426
Series C Preferred Units		31,992,709
Series B Preferred Units		17,794,455
Series A Preferred Units		4,918,881
Founder Units		2,252,916
Common Units		1,794,823
Management Incentive Units		10,786,757
Total shares issued		99,999,967

The unvested outstanding management incentive units and common units of BridgeBio Pharma LLC were exchanged for shares of the Corporation’s restricted common stock. Such unvested restricted shares are subject to the same time-based vesting conditions as the original management incentive units and common units terms and conditions.

On July 1, 2019, Merger Sub LLC was merged with and into BridgeBio Pharma LLC, the surviving entity, which became a wholly-owned subsidiary of the Corporation. At the conclusion of the Reorganization, the Corporation became the reporting entity.

Non-Binding Proposal to Acquire Common Stock of Eidos Therapeutics, Inc.

On August 8, 2019, the Corporation submitted to the board of directors of Eidos Therapeutics, Inc. (“Eidos”), a subsidiary of BridgeBio Pharma LLC, a non-binding proposal to acquire the outstanding shares of common stock of Eidos that are not owned by BridgeBio Pharma LLC. The proposal includes a suggested fixed exchange ratio of 1.30 shares of the Corporation’s common stock for each share of common stock of Eidos.

The proposal is subject to a number of contingencies, including the approval by the Board of Directors of Eidos and its special committee of independent directors. Additionally, the transaction will require an approval by a majority of the aggregate voting power represented by the shares of common stock of Eidos that are not owned by BridgeBio Pharma LLC.

BridgeBio Pharma LLC

Subsequent Events

17.	Subsequent Events

Initial Public Offering

On July 1, 2019, the Corporation completed the IPO of its common stock. As part of the IPO, the Corporation issued and sold 23,575,000 shares of its common stock, which included 3,075,000 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $17.00 per share. The Corporation received net proceeds of approximately $366.3 million from the IPO, after deducting underwriters’ discounts and commissions of $28.0 million and deferred offering costs of $6.5 million.

Reorganization

On June 13, 2019, the Corporation formed BridgeBio Pharma Merger Sub LLC (“Merger Sub LLC”), a Delaware limited liability company and direct wholly-owned subsidiary. On July 1, 2019, upon execution of the Reorganization, all outstanding units of BridgeBio Pharma, LLC were cancelled and exchanged for shares of common stock of the Corporation, as shown in the below table:

BridgeBio Pharma, LLC unit class	Number of BridgeBio Pharma, Inc. Shares Issued
Series D Preferred Units		30,459,426
Series C Preferred Units		31,992,709
Series B Preferred Units		17,794,455
Series A Preferred Units		4,918,881
Founder Units		2,252,916
Common Units		1,794,823
Management Incentive Units		10,786,757
Total shares issued		99,999,967

The unvested outstanding Management Incentive Units and Common Units of BridgeBio Pharma LLC were exchanged for shares of the Corporation’s restricted common stock. Such unvested restricted shares are subject to the same time-based vesting conditions as the vesting terms and conditions of the original Management Incentive Units and Common Units.

Hercules Loan and Security Agreement

Following the completion of the IPO on July 1, 2019, the terms of the Amended Hercules Term Loan were amended as follows: (i) a six month interest-only extension to July 1, 2021, (ii) a six month maturity extension to January 1, 2023, (iii) a reduction of 0.5% on the effective interest rate on Tranches I and II, and (iv) the option to pay up to 1.5% of scheduled cash pay interest on the entire facility as payment in kind, or PIK Interest, with such cash pay interest paid as PIK Interest at a 1:1.2 ratio.

Significant financing events in relation to controlled VIEs

Subsequent to June 30, 2019, BridgeBio made an additional investment in QED of $40.0 million, PTR of $7.0 million, Aspa of $3.6 million, Adrenas of $3.6 million and Fortify of $1.5 million.

Other financing events

In July 2019, BridgeBio purchased 882,353 shares of Eidos common stock from an existing Eidos investor for $26.4 million in a private purchase transaction.

In July 2019, BridgeBio purchased preferred stock of a biopharmaceutical entity for $7.0 million. BridgeBio may be required to purchase additional shares of preferred stock of up to $24.5 million upon achievement of certain development milestones by the biopharmaceutical entity.

Organization and Description of Business

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Organization and Description of Business

1.	Organization and Description of Business

BridgeBio Pharma LLC (“BridgeBio”) was established to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio’s pipeline of programs spans early discovery to late stage development. Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, the “Company”). BridgeBio is headquartered in Palo Alto, California.

Upon the closing of the Corporation’s IPO on July 1, 2019, all unitholders of BridgeBio Pharma LLC exchanged their units for shares of common stock of the Corporation, and BridgeBio Pharma LLC became a wholly-owned subsidiary of the Corporation. As the sole managing member, the Corporation will operate and control all of BridgeBio Pharma LLC businesses and affairs. These condensed consolidated financial statements as of June 30, 2019, including unit and per unit amounts, do not give effect to the Reorganization or the IPO as these transactions were completed subsequent to June 30, 2019. Refer to Note 17 for additional information.

Liquidity

The Company has incurred significant losses and negative cash flows from operations since its inception and has an accumulated deficit of $326.1 million as of June 30, 2019. The Company had cash and cash equivalents of $293.8 million as of June 30, 2019, of which $112.4 million was held by BridgeBio. The remaining cash and cash equivalents were held by the Company’s wholly-owned subsidiaries and controlled entities and these funds are designated for specific entity usage, except in limited circumstances.

The Company has historically financed its operations primarily through the sale of its equity securities and, to a lesser extent, debt borrowings. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.

The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates. The Company expects that its cash and cash equivalents, along with the $366.3 million of net proceeds received from the completion of the IPO in July 2019, will be sufficient to fund its operations for a period of at least one year from the date the condensed consolidated financial statements are filed with the Securities and Exchange Commission (“SEC”).

Fair Value Measurement

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Fair Value Measurement

3.	Fair Value Measurement

The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation:

	June 30, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	249,138	$	249,138	$	—	$	—
Total assets	$	249,138	$	249,138	$	—	$	—
Liabilities:
LEO Call Option liability	$	4,297	$	—	$	—	$	4,297
Total liabilities	$	4,297	$	—	$	—	$	4,297

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	395,780	$	395,780	$	—	$	—
Total assets	$	395,780	$	395,780	$	—	$	—
Liabilities:
LEO Call Option liability	$	3,009	$	—	$	—	$	3,009
Total liabilities	$	3,009	$	—	$	—	$	3,009

There were no financial assets outside of cash and cash equivalents as of June 30, 2019 and December 31, 2018. There were no transfers between Level 1, Level 2 or Level 3 during the periods presented.

LEO Call Option Liability

The valuation of the LEO Call Option (see Note 7) contains unobservable inputs that reflect management’s own assumptions for which there is little, if any, market activity at the measurement date. Accordingly, the LEO Call Option liability is remeasured to fair value on a recurring basis using unobservable inputs that are classified as Level 3 inputs.

The Company estimated the fair value of the LEO Call Option by estimating the fair value of various clinical, regulatory, and sales milestones based on the estimated risk and probability of achievement of each milestone, and allocated the value using a Black-Scholes option pricing model with the following assumptions:

	June 30, 2019		December 31, 2018
Probability of milestone achievement	12.0%-84.0%		12.0%-84.0%
Discount rate	1.8%-15.3%		2.7%-11.0%
Expected term (in years)	0.75-4.37		0.58-4.38
Expected volatility	67.5%-78.0%		67.0%-79.0%
Risk-free interest rate	2.92%-3.20%		2.51%-2.78%
Dividend yield		—		—

The following table sets forth a summary of the changes in the estimated fair value of the LEO Call Option:

	Total
	(in thousands)
Balance as of December 31, 2018	$	3,009
Change in fair value upon remeasurement recognized in other (income) expense		1,288
Balance as of June 30, 2019	$	4,297

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Balance Sheet Components

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Balance Sheet Components

4.	Balance Sheet Components

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Prepaid clinical and research related expenses	$	7,532	$	7,087
Other current assets		5,374		2,050
Total prepaid expenses and other current assets	$	12,906	$	9,137

Other Accrued Liabilities

Other accrued liabilities consist of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Accrued professional services	$	3,320	$	772
Accrued other liabilities		868		1,328
Total other accrued liabilities	$	4,188	$	2,100

Variable Interest Entities and Voting Interest Model

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Variable Interest Entities and Voting Interest Model

5.	Variable Interest Entities and Voting Interest Model

The entities consolidated by BridgeBio are comprised of wholly-owned subsidiaries and partially-owned entities consolidated under the VOE model and VIEs for which BridgeBio is the primary beneficiary under the VIE model. The results of operations of the consolidated entities are included within the BridgeBio condensed consolidated financial statements for the three and six months ended June 30, 2019 and 2018. As of June 30, 2019, there were no significant restrictions on the VIE assets or liabilities except for the cash held by its VIEs presented below. For VIEs, BridgeBio calculates the maximum exposure to loss to be equal to the amount invested in the equity of the VIE and the amount of outstanding convertible notes.

Included within Note 2 is a list of partially-owned entities that were determined to be under BridgeBio’s control as of June 30, 2019 and December 31, 2018. At each reporting period, the Company reassesses whether it has a majority voting interest for entities consolidated under the VOE model and whether it remains the primary beneficiary for VIEs consolidated under the VIE model.

Eidos

From the date of BridgeBio’s initial investment until June 22, 2018, the Eidos IPO closing date, Eidos was determined to be a VIE and BridgeBio consolidated Eidos as the primary beneficiary. Subsequent to the Eidos IPO, BridgeBio determined that Eidos was no longer a VIE due to it having sufficient equity at risk to finance its activities without additional subordinated financial support. From June 22, 2018 through June 30, 2019, BridgeBio determined that it held greater than 50% of the voting shares of Eidos and there were no other parties with substantive participating, liquidation or kick-out rights. BridgeBio consolidated Eidos under the VOE model as of June 30, 2019 and December 31, 2018.

In May 2019, the Company purchased 1,103,848 shares of Eidos common stock from an existing Eidos stockholder for $28.6 million in a private purchase transaction.

Consolidated VIEs

The entities identified as a “Controlled VIE” in Note 2 are VIEs for which BridgeBio was determined to be the primary beneficiary as of June 30, 2019. BridgeBio also had a majority ownership interest in these entities as of June 30, 2019 and December 31, 2018.

During the six months ended June 30, 2019, BridgeBio made investments in QED of $40.0 million, Quartz of $0.4 million, CoA of $5.1 million, Orfan of $3.5 million, Ferro of $4.5 million, Aspa of $8.0 million, Adrenas of $8.0 million, Origin of $10.0 million, Venthera of $1.5 million and Navire of $4.5 million in exchange for shares of redeemable convertible preferred stock of the respective entities. Based on the above noted equity financing transactions, BridgeBio concluded that there was no change in the consolidation conclusion during the period ended June 30, 2019.

The following table provides the assets and liabilities for all consolidated VIEs as of June 30, 2019:

	Adrenas		Aspa		PTR		QED		Venthera		All Other		Total
	(in thousands)
Assets:
Current assets:
Cash and cash equivalents	$	1,912	$	3,697	$	1,704	$	5,579	$	1,957	$	19,364	$	34,213
Prepaid expenses and other current assets		820		843		451		4,502		—		383		6,999
Total current assets		2,732		4,540		2,155		10,081		1,957		19,747		41,212
Property and equipment, net		566		310		76		321		—		290		1,563
Other assets		8		—		1		348		—		—		357
Total assets	$	3,306	$	4,850	$	2,232	$	10,750	$	1,957	$	20,037	$	43,132
Liabilities:
Current liabilities:
Accounts payable	$	1,338	$	1,814	$	420	$	2,625	$	836	$	2,621	$	9,654
Accrued compensation and benefits		278		31		247		1,204		—		750		2,510
Accrued research and development liabilities		82		99		145		3,151		32		2,469		5,978
Other accrued liabilities		171		10		134		267		—		117		699
Total current liabilities		1,869		1,954		946		7,247		868		5,957		18,841
Other liabilities		—		—		—		159		—		24		183
Total liabilities	$	1,869	$	1,954	$	946	$	7,406	$	868	$	5,981	$	19,024

The following table provides the assets and liabilities for all consolidated VIEs as of December 31, 2018:

	Adrenas		Aspa		PTR		QED		Venthera		All Other		Total
	(in thousands)
Assets:
Current assets:
Cash and cash equivalents	$	3,046	$	4,259	$	6,934	$	8,630	$	2,913	$	6,713	$	32,495
Prepaid expenses and other current assets		665		1,722		28		3,240		—		321		5,976
Total current assets		3,711		5,981		6,962		11,870		2,913		7,034		38,471
Property and equipment, net		584		129		88		181		—		277		1,259
Other assets		7		—		41		—		—		28		76
Total assets	$	4,302	$	6,110	$	7,091	$	12,051	$	2,913	$	7,339	$	39,806
Liabilities:
Current liabilities:
Accounts payable	$	1,876	$	1,187	$	621	$	3,537	$	333	$	1,737	$	9,291
Accrued compensation and benefits		377		30		287		1,392		—		467		2,553
Accrued research and development liabilities		227		728		—		4,390		—		1,251		6,596
Other accrued liabilities		28		32		8		229		9		82		388
Total current liabilities		2,508		1,977		916		9,548		342		3,537		18,828
Other liabilities		—		—		—		150		—		29		179
Total liabilities	$	2,508	$	1,977	$	916	$	9,698	$	342	$	3,566	$	19,007

VIEs included in the “All Other” category of the above table are not significant individually for separate presentation. Going forward, BridgeBio may not provide any further investment in certain of these VIEs.

Noncontrolling Interests

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Noncontrolling Interests

6.	Noncontrolling Interests

As of June 30, 2019, the Company has both redeemable convertible noncontrolling interests and noncontrolling interests in consolidated partially-owned entities, for which BridgeBio has a majority voting interest under the VOE model and for which BridgeBio is the primary beneficiary under the VIE model. These balances are reported as separate components outside members’ deficit and as part of members’ deficit, respectively, in “Redeemable convertible noncontrolling interests” and “Noncontrolling interests” in the condensed consolidated balance sheets.

The Company adjusts the carrying value of noncontrolling interest to reflect the book value attributable to noncontrolling shareholders of consolidated partially-owned entities when there is a change in the ownership during the respective reporting period. During the three and six months ended June 30, 2019, such adjustments in the aggregate amounts of $25.4 million and $28.4 million are recorded to accumulated deficit. During the three and six months ended June 30, 2018, such adjustments in the aggregate amounts of $56.2 million and $60.1 million are recorded to accumulated deficit. All such adjustments are disclosed within the “Transfers to (from) noncontrolling interest” line item in the Condensed Consolidated Statements of Redeemable Convertible Preferred Units, Redeemable Founder Units, Redeemable Common Units, Management Incentive Units, Redeemable Convertible Noncontrolling Interests and Members’ Deficit.

The following table provides a rollforward of the redeemable convertible noncontrolling interests balance, as follows:

	Orfan			QED			Total
	(in thousands)
Balance as of December 31, 2018	$	8		$	114		$	122
Net loss attributable to redeemable convertible noncontrolling interest		(34	)		(756	)		(790	)
Transfers to redeemable convertible noncontrolling interest		57			813			870
Balance as of March 31, 2019		31			171			202
Net loss attributable to redeemable convertible noncontrolling interest		(23	)		(662	)		(685	)
Transfers to redeemable convertible noncontrolling interest		47			611			658
Balance as of June 30, 2019	$	55		$	120		$	175

The following table provides a rollforward of the noncontrolling interests balance:

	Adrenas			Aspa			Eidos			PTR			Venthera			All Other			Total
	(in thousands)
Balance as of December 31, 2018	$	217		$	245		$	58,185		$	2,728		$	449		$	537		$	62,361
Issuance of noncontrolling interest		2			2			1,027			34			1			254			1,320
Transfers to (from) noncontrolling interest		874			472			(337	)		(10	)		(1	)		1,100			2,098
Net loss attributable to noncontrolling interest		(451	)		(222	)		(4,365	)		(1,580	)		(192	)		(651	)		(7,461	)
Balance as of March 31, 2019		642			497			54,510			1,172			257			1,240			58,318
Issuance (repurchase) of noncontrolling interest		3			2			(27,030	)		—			—			1			(27,024	)
Transfers to (from) noncontrolling interest		32			208			23,751			4			273			514			24,782
Net loss attributable to noncontrolling interest		(554	)		(471	)		(5,200	)		(552	)		(353	)		(555	)		(7,685	)
Balance as of June 30, 2019	$	123		$	236		$	46,031		$	624		$	177		$	1,200		$	48,391

PellePharm Investment

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

PellePharm Investment

7.	PellePharm Investment

PellePharm is a clinical stage biopharmaceutical company developing BBP-009, a topical gel formulation of patidegib, a hedgehog inhibitor, for the treatment of Gorlin Syndrome and High-Frequency Basal Cell Carcinoma. In July 2015, BridgeBio made an initial investment of $4.5 million in PellePharm and in a series of transactions through December 2016, the Company increased its ownership interest to greater than 50%. BridgeBio determined that its initial investment in PellePharm represented a variable interest, but that BridgeBio was not the primary beneficiary until December 2016.

On November 19, 2018, PellePharm entered into the LEO Agreement with LEO, pursuant to which LEO was granted an exclusive, irrevocable option to acquire PellePharm. The LEO Call Option is exercisable by LEO on or before the occurrence of certain events relating to PellePharm’s clinical development programs and no later than July 30, 2021. The Company accounts for the LEO Call Option as a current liability in its condensed consolidated financial statements because BridgeBio is obligated to sell its shares in PellePharm to LEO at a pre-determined price, if the option is exercised. The Company will remeasure the LEO Call Option to fair value at each subsequent condensed consolidated balance sheet date until the LEO Call Option is either exercised or expires.

The date the LEO Agreement was entered into was determined to be a VIE reconsideration event. Based on the Company’s assessment, BridgeBio concluded that PellePharm remains a VIE after the reconsideration event as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, based on changes to PellePharm’s governance structure and Board of Directors composition as a result of the LEO Agreement, BridgeBio is no longer the primary beneficiary as it no longer has the power over the key decisions that most significantly impact PellePharm’s economic performance. Accordingly, BridgeBio deconsolidated PellePharm on November 19, 2018. After the deconsolidation in November 2018, PellePharm is considered a related party of BridgeBio.

Subsequent to the deconsolidation of PellePharm, BridgeBio accounted for its retained common stock investment as an equity method investment and its retained preferred stock investment as a cost method investment. As of June 30, 2019 and December 31, 2018, the aggregate carrying amount of the Company’s equity method investment in PellePharm was zero and $0.2 million. As of June 30, 2019 and December 31, 2018, the aggregate carrying amount for the Company’s cost method investment in PellePharm was $7.5 million and $16.8 million. After the equity method investment was reduced to zero during the three months ended March 31, 2019, BridgeBio has subsequently recorded its percentage of net losses consistent with its preferred stock ownership percentage of 62%. The carrying amount of BridgeBio’s investment in PellePharm in the condensed consolidated balance sheets represents its maximum loss exposure related to its VIE investment in PellePharm.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Commitments and Contingencies

8.	Commitments and Contingencies

On December 31, 2018, Children Hospital Research Center at Oakland (“CHRCO”) filed, but did not serve, a civil complaint against Dr. Ervin Epstein, Co-Founder and Chief Medical Officer of PellePharm and PellePharm in the Northern District of California. CHRCO asserts four causes of action against Dr. Epstein (conversion, breach of contract, breach of the implied covenant of good faith and fair dealing, and specific performance), and one related cause of action against PellePharm (constructive trust). All five causes of action are generally directed to a set of accusations relating to Dr. Epstein’s prior employment at CHRCO. In its complaint, CHRCO seeks monetary damages as well as equitable relief in the form of a constructive trust and an injunction. CHRCO has since withdrawn its complaint in the Northern District of California and filed, and as of May 16, 2019, has not yet served a revised civil complaint against PellePharm and Dr. Epstein in the Superior Court of the State of California, County of San Francisco, asserting the same five causes of action. On April 11, 2019, CHRCO filed an unopposed ex parte application with the Court to extend the deadline to serve the complaint to June 11, 2019. Dr. Epstein and PellePharm dispute all of CHRCO’s allegations and believe they lack merit and they intend to contest the case vigorously. No responsive pleading is required at this time, nor has Dr. Epstein or PellePharm provided one.

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is unable to predict the outcome of these matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or range of loss and accordingly has not accrued a related liability.

Hercules Term loan

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Hercules Term Loan

9.	Hercules Term Loan

Hercules Loan and Security Agreement

In June 2018, the Company executed a Loan and Security Agreement with Hercules Capital, Inc. (“Hercules”), under which the Company borrowed $35.0 million (“Tranche I”). The term of the loan was approximately 42 months, with a maturity date of January 1, 2022 (the “Maturity Date”). No principal payments were due during an interest-only period, commencing on the initial borrowing date and continuing through July 1, 2020 (the “Amortization Date”). The outstanding balance of the loan was to be repaid monthly beginning on the Amortization Date and extending through the Maturity Date. Tranche I bears interest at a floating rate equal to the greater of: (i) the prime rate as reported in the Wall Street Journal plus 4.35% and (ii) 9.35% (9.85% as of June 30, 2019 based on the prime rate as of that date), payable monthly.

In December 2018, the Company executed the First Amendment to the Loan and Security Agreement, whereby the Company borrowed an additional $20.0 million (“Tranche II”) to increase the total principal balance outstanding to $55.0 million. Upon draw of the additional $20.0 million, the interest-only period on the entire facility was extended until January 1, 2021 (the “Amended Amortization Date”) and the maturity date for the entire facility was July 1, 2022 (the “Amended Maturity Date”). Tranche II bears interest at a floating rate equal to the greater of: (i) the prime rate as reported in the Wall Street Journal plus 3.35% and (ii) 9.10% (9.10% as of June 30, 2019), payable monthly.

In May 2019, the Company executed the Second Amendment to the Loan and Security Agreement whereby the Company borrowed an additional $20.0 million (“Tranche III”) to increase the total principal balance outstanding to $75.0 million (the “Amended Hercules Term Loan”). Tranche III bears interest at a floating rate equal to the greater of: (i) the prime rate as reported in the Wall Street Journal plus 3.10% and (ii) 9.10% (9.10% as of June 30, 2019), payable monthly. The outstanding balance of the Amended Hercules Term Loan is to be repaid monthly beginning on the Amended Amortization Date and extending through the Amended Maturity Date.

During the three and six months ended June 30, 2019, the Company recognized interest expense related to the Amended Hercules Term Loan of $1.9 million and $3.6 million, of which $0.3 million and $0.7 million relate to amortization of debt discount. No material interest expense was recognized in relation to Hercules Term Loan during the six months ended June 30, 2018.

License Agreements

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

License Agreements

10.	License Agreements

Stanford License Agreement

In April 2016, Eidos entered into a license agreement with the Board of Trustees of the Leland Stanford Junior University (“Stanford University”) relating to Eidos’ drug discovery and development initiatives. Under this agreement, Eidos has been granted certain worldwide exclusive licenses to make, use and sell products that are covered by licensed patent rights. During the three and six months ended June 30, 2019, Eidos recognized research and development expense of zero and $0.2 million in connection with this agreement.

The University of Texas License Agreement

In March 2017, Navire entered into a collaboration and license agreement with The Board of Regents of The University of Texas System (“Board of Regents”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson” and collectively “University of Texas”) relating to Navire’s drug discovery and development initiatives. Under this agreement, Navire and the University of Texas will carry out the development, manufacture and commercialization of licensed product under exclusive licenses granted by the University of Texas. The Company issued the Board of Regents shares of common stock of Navire valued at zero and $0.2 million during the three and six months ended June 30, 2019 that was recognized as research and development expense. During the three and six months ended June 30, 2019, Navire recognized additional research and development expense of $0.5 million and $1.0 million in connection with this agreement.

The Regents of the University of California License Agreement

In September 2016, TheRas, Inc. (“TheRas”) entered into a license agreement with The Regents of the University of California (“UCSF”) relating to TheRas’ drug discovery and development initiatives. Under this agreement, TheRas has been granted certain worldwide exclusive licenses to use the licensed compounds (the “UCSF License”). Nominal expense was recognized in connection with this agreement during the three and six months ended June 30, 2019.

Leidos Biomedical Research License and Cooperative Research and Development Agreements

In March 2017, TheRas entered into a cooperative research and development agreement (“Leidos CRADA”) with Leidos Biomedical Research, Inc. (“Leidos”). In December 2018, TheRas and Leidos entered into a license agreement (“Leidos License,” and together with the Leidos CRADA, the “Leidos Agreements”) under which TheRas has been granted certain worldwide exclusive licenses to use the licensed compounds. The Leidos Agreements are related to TheRas’ drug discovery and development initiatives. During the three and six months ended June 30, 2019, TheRas recognized research and development expenses of $0.4 million and $0.6 million in connection with the Leidos Agreements.

St. Jude License Agreement

In April 2017, CoA entered into a license agreement with St. Jude Children’s Research Hospital, Inc., (“St. Jude”) relating to CoA’s drug discovery and development initiatives. Under this agreement, CoA has been granted a worldwide exclusive license to use a licensed compound. During the three and six months ended June 30, 2019, CoA recognized research and development expense of $0.2 million and $0.3 million in connection with this agreement.

K-Gen License Agreement

In March 2018, Ferro entered into a license agreement with K-Gen, Inc. (“K-Gen”) relating to Ferro’s drug discovery and development initiatives. Under this agreement, Ferro has been granted certain worldwide exclusive licenses to use the licensed compounds. Nominal expense was recognized in connection with this agreement during the three and six months ended June 30, 2019.

Memorial Sloan Kettering Cancer Center License Agreement

In April 2018, Venthera Inc. (“Venthera”) entered into a license agreement with Memorial Sloan Kettering Cancer Center (“MSK”) relating to Venthera’s drug discovery and development initiatives. Under this agreement, Venthera has been granted certain worldwide exclusive licenses to use the licensed products. No expense was recognized in connection with this agreement during the three and six months ended June 30, 2019.

University of Massachusetts License Agreement

In April 2018, Aspa entered into a license agreement with the University of Massachusetts (“UM”) relating to Aspa’s drug discovery and development initiatives. Under this agreement, Aspa has been granted certain worldwide exclusive licenses to use the licensed compounds. During the three and six months ended June 30, 2019, Aspa recognized nominal research and development expense in connection with this agreement.

NeuroVive License Agreement

In June 2018, Fortify Therapeutics, Inc. (“Fortify”) entered into a license agreement with NeuroVive Pharmaceutical AB (“NeuroVive”) relating to Fortify’s drug discovery and development initiatives. Under this agreement, Fortify has been granted certain worldwide exclusive licenses to use the licensed compounds. During the three and six months ended June 30, 2019, Fortify recognized nominal research and development expense in connection with this agreement.

Life License Agreement

In August 2018, BridgeBio entered into a license agreement with Life Technologies Corporation (“Life”) relating to Adrenas’ and Aspa’s drug discovery and development initiatives. Under this agreement, BridgeBio, Adrenas and Aspa have been granted certain worldwide non-exclusive licenses to use the licensed compounds. During the three and six months ended June 30, 2019, Aspa recognized research and development expense of $0.4 million and $0.4 million in connection with this agreement.

Unnamed Entity #1 License Agreement

In December 2018, Unnamed Entity #1 entered into a license agreement relating to its drug discovery and development initiatives. Under this agreement, Unnamed Entity #1 has been granted certain worldwide exclusive licenses to use the licensed compounds. No expense was recognized in connection with this agreement during the three and six months ended June 30, 2019.

Foundation Medicine Diagnostics Agreement

In November 2018, QED and Foundation Medicine, Inc. (“FMI”) entered into a diagnostics agreement relating to QED’s drug discovery and development initiatives. During the three and six months ended June 30, 2019, QED recognized research and development expenses of $0.3 million and $0.3 million in connection with this agreement.

Other License and Collaboration Agreements

In addition to the agreements described above, the Company has also entered into other license and collaboration agreements with various institutions and business entities on terms similar to those described above, none of which are material individually or in the aggregate.

Asset Acquisitions

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Asset Acquisitions

11.	Asset Acquisitions

Unnamed Entity #2 Asset Acquisition

In June 2019, Unnamed Entity #2 entered into a Unit Purchase and Sale Agreement with the owners of a biopharmaceutical entity to acquire 100% of the outstanding equity of the entity. Unnamed Entity #2 accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired were concentrated in a group of similar identified assets, in-process research and development (“IPR&D”), thus satisfying the requirements of the screen test in ASU 2017-01. The assets acquired and liabilities assumed in the transaction were measured based on their fair values.

The fair value of the IPR&D acquired was $0.5 million and was charged to research and development expense as it had no alternative future use at the time of the acquisition. If certain substantive milestones are met in the future, Unnamed Entity #2 could be required to pay up to $7.0 million in regulatory milestone payments, $65.0 million in sales milestone payments, and pay royalties of up to low single-digit percentages on future net sales. Royalties may increase to up to mid single-digit percentages in certain circumstances.

Phoenix Tissue Repair, Inc. (“PTR”) Asset Acquisition

In July 2017, PTR entered into the Contribution Agreement and Asset Purchase Agreement with Shire Human Genetic Therapies, Inc. and its subsidiary Lotus Tissue Repair, Inc. to acquire the right, title, and interest in certain intellectual property, research program assets, and contracts relating to recombinant human collagen type VII. As consideration, in 2017, PTR made an upfront cash payment of $1.5 million and issued 10,019,900 shares of PTR common stock valued at a nominal fair value at issuance. There were no material direct transaction costs related to the transaction.

During the three and six months ended June 30, 2019, PTR made a milestone payment of zero and $2.0 million in connection with this agreement related to the Phase I initiation milestone being met. This amount was charged to research and development expense as the underlying in-process research and development asset has no alternative future use.

If certain substantive milestones are met in the future, PTR could be required to pay up to $25.0 million in regulatory milestone payments, $60.0 million in sales milestone payments, and pay royalties of up to low single-digit percentages on future net sales, if any.

Related Party Transactions

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Related Party Transactions

12.	Related Party Transactions

Nonrecourse Notes

In 2016 and 2017 the Company entered into nonrecourse notes (the “Notes”) with two founders. The Notes were issued to facilitate the purchase of Series B Preferred Units by two founders. The principal amount of the Notes was $0.3 million and mature in May 2021. The Notes were accounted for as an option for which the Company recognized equity-based compensation expense on issuance. The repayment of the Notes is recorded as an addition to the Series B Preferred Units balance as payments are received and the Notes were paid in full in February 2019.

PellePharm

During the three and six months ended June 30, 2019, the Company provided nominal services to PellePharm.

Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Temporary Equity [Line Items]

Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units

13.	Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units

As of June 30, 2019, the Fourth Amended and Restated Limited Liability Company Agreement provided for the issuance of Series A Preferred Units, Series B Preferred Units, Series C Preferred Units, Series D Preferred Units, Founder Units, Common Units and Management Incentive Units.

Outstanding Preferred Units, Founder Units and Common Units consist of the following:

	Units Issued and Outstanding		Original Issue Price Per Unit		Carrying Value		Liquidation Preference
	(in thousands, except unit and per unit amounts)
Series A Preferred Units		24,935,281	$	0.2627	$	4,919	$	13,542
Series B Preferred Units		90,909,090	$	0.4400		39,945		47,096
Series C Preferred Units		141,155,758	$	0.9656		135,482		147,155
Series D Preferred Units		150,955,597	$	1.9823		298,698		299,239
Total Preferred Units as of June 30, 2019		407,955,726				479,044		507,032
Founder Units		11,420,741	$	—		1,754		6,202
Common Units		7,868,637	$	—		1,672		4,274
Total outstanding units as of June 30, 2019		427,245,104			$	482,470	$	517,508

	Units Issued and Outstanding		Original Issue Price Per Unit		Carrying Value		Liquidation Preference
	(in thousands, except unit and per unit amounts)
Series A Preferred Units		24,935,281	$	0.2627	$	4,919	$	13,542
Series B Preferred Units		90,909,090	$	0.4400		39,766		47,096
Series C Preferred Units		141,155,758	$	0.9656		135,482		147,155
Series D Preferred Units		150,955,597	$	1.9823		298,698		299,239
Total Preferred Units as of December 31, 2018		407,955,726				478,865		507,032
Founder Units		11,420,741	$	—		1,754		6,202
Common Units		7,197,783	$	—		1,619		3,910
Total outstanding units as of December 31, 2018		426,574,250			$	482,238	$	517,144

As of June 30, 2019 and December 31, 2018, BridgeBio has classified all of its outstanding Preferred Units, Founder Units, Common Units, and Management Incentive Units outside of members’ deficit in the accompanying condensed consolidated financial statements because these units contain certain redemption features that are not solely within the control of BridgeBio. Specifically, in the event an IPO does not take place by a pre-defined date, the majority preferred unitholders could force a “liquidation event” that is not solely within BridgeBio’s control. The Company did not adjust the carrying values of the Preferred Units, Founder Units and Common Units to their deemed liquidation values of such units since a liquidation event was not probable as of June 30, 2019 and December 31, 2018.

As discussed in Note 17, immediately prior to the closing of the IPO on July 1, 2019, holders of units of BridgeBio Pharma LLC exchanged all such units for an aggregate of 99,999,967 shares of common stock of the Corporation. At the completion of the Reorganization, there were no units outstanding.

MyoKardia Distribution

In April 2015, the Company acquired an interest in MyoKardia, Inc. for $1.0 million. This investment was subsequently disposed of in 2016 and the Company recognized a gain on disposal of $1.2 million in the year ended December 31, 2016. Prior to the execution of the merger of BridgeBio and BridgeBio LLC in June 2017, the Company distributed $1.2 million to its members in proportion to the number of units then outstanding and was required to distribute the remaining proceeds of $1.0 million. This liability is included in accrued distributions to unitholders in the condensed consolidated balance sheet as of December 31, 2018. The accrued distributions of $1.0 million were paid to unitholders in February 2019.

Equity-Based Compensation

6 Months Ended

Jun. 30, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock/Equity-based Compensation

4.	Stock-based Compensation

2019 Stock Option and Incentive Plan

The following table summarizes the Corporation’s stock option activity for the period from May 17, 2019 through June 30, 2019:

	Options Available for Grant			Options Outstanding		Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of May 17, 2019		—			—	$	—		—	$	—
Authorized		11,500,000			—	$	—
Granted		(3,744,629	)		3,744,629	$	17.00
Outstanding as of June 30, 2019		7,755,371			3,744,629	$	17.00		6.02	$	37,334
Exercisable as of June 30, 2019					—	$	—		—	$	—

Determination of Fair Value

The fair value of each stock option grant was determined by the Corporation at the grant date using a Black-Scholes option-pricing model with the following assumptions:

	May 17, 2019 – June 30, 2019
Expected term (in years)	6.02-6.08
Expected volatility		37.5	%
Risk-free interest rate		1.86	%
Dividend yield		—
Weighted average fair value of share-based awards granted	$	6.64

2019 Employee Stock Purchase Plan

As of June 30, 2019, no shares were issued and outstanding under the ESPP.

BridgeBio Pharma LLC

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Stock/Equity-based Compensation

14.	Equity-Based Compensation

The Company recorded equity-based compensation in the following expense categories in its condensed consolidated statements of operations for employees and non-employees:

	Six Months Ended June 30, 2019
	BridgeBio		Eidos		Other		Total
	(in thousands)
Research and development	$	—	$	1,004	$	19	$	1,023
General and administrative		3,355		1,126		17		4,498
Total equity-based compensation	$	3,355	$	2,130	$	36	$	5,521

	Six Months Ended June 30, 2018
	BridgeBio		Eidos		Other		Total
	(in thousands)
Research and development	$	—	$	620	$	62	$	682
General and administrative		646		386		54		1,086
Total equity-based compensation	$	646	$	1,006	$	116	$	1,768

For the three and six months ended June 30, 2019, total BridgeBio equity-based compensation from Common Units was less than $0.1 million and $0.1 million, and from Management Incentive Units was $2.1 million and $3.3 million.

For the three and six months ended June 30, 2018, total BridgeBio equity-based compensation from Common Units was less than $0.1 million and $0.1 million, and from Management Incentive Units was $0.3 million and $0.6 million.

The estimated grant-date fair value of each Common Unit and Management Incentive Unit award was calculated using the Black-Scholes option pricing model, based on assumptions as follows:

	Six Months Ended June 30,
	2019		2018
Expected term (in years)		1.50	0.75-1.50
Expected volatility	48.0%-49.0%		40.0%-45.0%
Risk-free interest rate	2.34%-2.56%		1.70%-2.22%
Dividend yield		—		—

BridgeBio had 9,098,522 authorized Common Units at June 30, 2019 and December 31, 2018. The following table summarizes BridgeBio’s Common Units activity:

	Number of Common Units Outstanding		Weighted- Average Grant Date Fair Value
Balance as of December 31, 2018		7,197,783	$	0.08
Vested		670,854	$	0.08
Balance as of June 30, 2019		7,868,637	$	0.08

As of June 30, 2019, there were 1,229,885 unvested Common Units and total unrecognized compensation related to the unvested Common Units was $0.1 million, which the Company expects to be recognized over a weighted-average period of 0.9 years. All unvested Common Units as of June 30, 2019 will vest through May 2020.

The following table summarizes BridgeBio’s authorized Management Incentive Units activity:

	Number of Authorized Units
Balance as of December 31, 2018		48,695,602
Authorized and granted		24,111,064
Cancelled		(5,000	)
Balance as of June 30, 2019		72,801,666

The following table summarizes BridgeBio’s vested Management Incentive Units activity:

	Number of Management Incentive Units Outstanding		Weighted- Average Grant Date Fair Value
Balance as of December 31, 2018		19,117,628	$	0.08
Vested		6,460,380	$	0.36
Balance as of June 30, 2019		25,578,008	$	0.14

As of June 30, 2019, there were 47,223,658 unvested Management Incentive Units and unrecognized compensation related to the unvested Management Incentive Units was $30.1 million, which the Company expects to recognize over a weighted-average period of 4.0 years. All unvested Management Incentive Units as of June 30, 2019 will vest through February 2024.

Eidos

Common stock

Eidos has reserved shares of common stock for issuance as follows:

	As of June 30,
	2019		2018
Options issued and outstanding		1,454,461		881,612
Options available for future grants		537,345		490,360
Eidos ESPP shares available for future grants		104,540		143,520
Total		2,096,346		1,515,492

Stock options

The following table summarizes Eidos’s stock option activity for the six months ended June 30, 2019:

	Options Available for Grant			Options Outstanding			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of December 31, 2018		747,057			1,329,762		$	8.55		9.40	$	6,928
Granted		(209,712	)		209,712		$	27.22
Exercised		—			(85,013	)	$	1.32
Outstanding as of June 30, 2019		537,345			1,454,461		$	11.66		9.07	$	28,246
Vested and expected to vest as of June 30, 2019					251,447		$	6.26		8.69	$	6,240
Exercisable as of June 30, 2019					1,454,461		$	11.66		9.07	$	28,246

Employee stock options valuation

The fair value of employee and non-employee director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

	Six Months Ended June 30,
	2019			2018
Expected term (in years)		6.07			6.08
Expected volatility		72.31	%		69.59	%
Risk-free interest rate		2.10	%		2.78	%
Dividend yield		—			—
Weighted average fair value of share-based awards granted	$	18.22		$	7.50

Stock options granted to non-employees

Stock-based compensation related to stock options granted to non-employees is recognized as the stock options are earned. The fair value of the stock options granted to non-employees was calculated at each reporting date using the Black-Scholes option-pricing model with the following assumptions:

	Six Months Ended June 30,
	2019			2018
Expected term (in years)		6.08			9.70
Expected volatility		73.54	%		68.31	%
Risk-free interest rate		2.74	%		2.84	%
Dividend yield		—			—

During the three and six months ended June 30, 2019 and 2018, Eidos granted 0, 18,500, 35,880 and 35,880 shares, respectively, to non-employee consultants. Eidos recognized stock-based compensation expense for non-employee awards during the three and six months ended June 30, 2019 and 2018 of $0.1 million and $0.1 million, and $0.1 million and $0.2 million, respectively.

Stock-based compensation

As of June 30, 2019, there was $12.5 million of total unrecognized compensation cost related to unvested equity-based compensation arrangements under the Eidos 2016 Equity Incentive Plan and Eidos 2018 Stock Option and Incentive Plan. The unrecognized equity-based compensation cost is expected to be recognized over a weighted-average period of 2.66 years.

Income Taxes

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Income Taxes

15.	Income Taxes

BridgeBio is a “pass-through” entity under the Internal Revenue Code of 1986, as amended (the “Code”) and the members are taxed directly on their respective ownership interests in the condensed consolidated income. Therefore, no provision or liability for federal income tax has been included in the accompanying condensed consolidated financial statements related to BridgeBio. Upon conversion to a corporation, the Company will become subject to U.S. federal and state income taxes.

The Company’s tax provision and the resulting effective tax rate for interim periods is determined based upon its estimated annual effective tax rate adjusted for the effect of discrete items arising in that quarter.

The Company’s policy is to recognize interest and penalties associated with uncertain tax benefits as part of the income tax provision and include accrued interest and penalties with the related income tax liability on the consolidated balance sheet. To date, the Company has not recognized any interest and penalties in its consolidated statements of operations, nor has it accrued for or made payments for interest and penalties. The Company’s unrecognized gross tax benefits would not reduce the estimated annual effective tax rate if recognized because it has recorded a full valuation allowance on its deferred tax assets.

Net loss per Unit

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Net loss per Unit

16.	Net Loss per Unit

The following outstanding units were excluded from the computation of the diluted net loss per unit for the periods presented because their effect would have been anti-dilutive.

	June 30,
	2019		2018
Preferred Units		407,955,726		257,000,129
Management Incentive Units		72,801,666		45,678,102
Unvested Common Units		1,229,885		2,571,593
Total		481,987,277		305,249,824

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2019

Basis of Presentation

Underwriting Commissions and Offering Costs

Organizational Costs

Equity-Based Compensation

BridgeBio Pharma LLC

Basis of Presentation

Variable Interest Entities and Voting Interest Entities

BridgeBio has either created or made investments in the following entities:

Consolidated Entities	Relationship as of June 30, 2019	Date Control First Acquired	Ownership % as of June 30, 2019			Ownership % as of December 31, 2018
			(unaudited)
TheRas, Inc.	Wholly-owned subsidiary	August 2016		100	%		100	%
BridgeBio Services, Inc.	Wholly-owned subsidiary	April 2017		100	%		100	%
Fortify Therapeutics, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Sub20, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Unnamed Entity #1	Wholly-owned subsidiary	December 2018		100	%		100	%
Unnamed Entity #2	Wholly-owned subsidiary	April 2019		100	%		—
Unnamed Entity #3	Wholly-owned subsidiary	May 2019		100	%		—
Eidos Therapeutics, Inc.⁽¹⁾	Partially-owned subsidiary	April 2016		65.1	%		62.5	%
Molecular Skin Therapeutics, Inc.	Controlled VIE	July 2016		58.2	%		61.7	%
Quartz Therapeutics, Inc.	Controlled VIE	October 2016		89.0	%		89.0	%
PellePharm, Inc.⁽²⁾	VIE	December 2016		43.3	%		43.3	%
Navire Pharma, Inc.	Controlled VIE	February 2017		78.9	%		78.8	%
CoA Therapeutics, Inc.	Controlled VIE	February 2017		99.6	%		99.5	%
Dermecular Therapeutics, Inc.	Controlled VIE	April 2017		87.6	%		87.6	%
Phoenix Tissue Repair, Inc.	Controlled VIE	July 2017		56.4	%		56.7	%
QED Therapeutics, Inc.	Controlled VIE	January 2018		96.6	%		94.4	%
Adrenas Therapeutics, Inc.	Controlled VIE	January 2018		88.7	%		90.1	%
Orfan Biotech, Inc.	Controlled VIE	January 2018		89.6	%		85.1	%
Ferro Therapeutics, Inc.	Controlled VIE	March 2018		90.0	%		89.4	%
Origin Biosciences, Inc.	Controlled VIE	April 2018		99.8	%		100	%
Venthera, Inc.	Controlled VIE	April 2018		81.8	%		82.0	%
Aspa Therapeutics, Inc.	Controlled VIE	June 2018		90.3	%		92.5	%

(1)	Subsequent to the Eidos Therapeutics, Inc. (“Eidos”) initial public offering in June 2018 and through June 30, 2019, BridgeBio has a majority voting interest in Eidos and consolidates Eidos under the VOE model. Refer to Note 5.

(2)

Use of Estimates

Cash, Cash Equivalents and Restricted Cash

	June 30, 2019		June 30, 2018
	(in thousands)
Cash and cash equivalents	$	293,803	$	252,379
Restricted cash		424		359
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	294,227	$	252,738

Fair Value Measurements

Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date;

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Deferred Offering Costs

Net Loss per Share

Net Loss per Unit

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

Recently Issued Accounting Pronouncements Not Yet Adopted

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity

The following table summarizes the Corporation’s stock option activity for the period from May 17, 2019 through June 30, 2019:

	Options Available for Grant			Options Outstanding		Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of May 17, 2019		—			—	$	—		—	$	—
Authorized		11,500,000			—	$	—
Granted		(3,744,629	)		3,744,629	$	17.00
Outstanding as of June 30, 2019		7,755,371			3,744,629	$	17.00		6.02	$	37,334
Exercisable as of June 30, 2019					—	$	—		—	$	—

Summary of Assumptions used to Determine Fair Value of Stock Option Awards Granted to Employees, Directors and Nonemployees

The fair value of each stock option grant was determined by the Corporation at the grant date using a Black-Scholes option-pricing model with the following assumptions:

	May 17, 2019 – June 30, 2019
Expected term (in years)	6.02-6.08
Expected volatility		37.5	%
Risk-free interest rate		1.86	%
Dividend yield		—
Weighted average fair value of share-based awards granted	$	6.64

Subsequent Events (Tables)

6 Months Ended

Jun. 30, 2019

Summary of Outstanding Units Class of BridgeBio Pharma, LLC Cancelled and Exchanged for Shares of Common Stock Upon Reorganization

BridgeBio Pharma, LLC unit class	Number of BridgeBio Pharma, Inc. Shares Issued
Series D Preferred Units		30,459,426
Series C Preferred Units		31,992,709
Series B Preferred Units		17,794,455
Series A Preferred Units		4,918,881
Founder Units		2,252,916
Common Units		1,794,823
Management Incentive Units		10,786,757
Total shares issued		99,999,967

BridgeBio Pharma LLC

Summary of Outstanding Units Class of BridgeBio Pharma, LLC Cancelled and Exchanged for Shares of Common Stock Upon Reorganization

BridgeBio Pharma, LLC unit class	Number of BridgeBio Pharma, Inc. Shares Issued
Series D Preferred Units		30,459,426
Series C Preferred Units		31,992,709
Series B Preferred Units		17,794,455
Series A Preferred Units		4,918,881
Founder Units		2,252,916
Common Units		1,794,823
Management Incentive Units		10,786,757
Total shares issued		99,999,967

Summary of Significant Accounting Policies (Tables) - BridgeBio Pharma LLC

6 Months Ended

Jun. 30, 2019

Summary of Investments

BridgeBio has either created or made investments in the following entities:

Consolidated Entities	Relationship as of June 30, 2019	Date Control First Acquired	Ownership % as of June 30, 2019			Ownership % as of December 31, 2018
			(unaudited)
TheRas, Inc.	Wholly-owned subsidiary	August 2016		100	%		100	%
BridgeBio Services, Inc.	Wholly-owned subsidiary	April 2017		100	%		100	%
Fortify Therapeutics, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Sub20, Inc.	Wholly-owned subsidiary	June 2018		100	%		100	%
Unnamed Entity #1	Wholly-owned subsidiary	December 2018		100	%		100	%
Unnamed Entity #2	Wholly-owned subsidiary	April 2019		100	%		—
Unnamed Entity #3	Wholly-owned subsidiary	May 2019		100	%		—
Eidos Therapeutics, Inc.⁽¹⁾	Partially-owned subsidiary	April 2016		65.1	%		62.5	%
Molecular Skin Therapeutics, Inc.	Controlled VIE	July 2016		58.2	%		61.7	%
Quartz Therapeutics, Inc.	Controlled VIE	October 2016		89.0	%		89.0	%
PellePharm, Inc.⁽²⁾	VIE	December 2016		43.3	%		43.3	%
Navire Pharma, Inc.	Controlled VIE	February 2017		78.9	%		78.8	%
CoA Therapeutics, Inc.	Controlled VIE	February 2017		99.6	%		99.5	%
Dermecular Therapeutics, Inc.	Controlled VIE	April 2017		87.6	%		87.6	%
Phoenix Tissue Repair, Inc.	Controlled VIE	July 2017		56.4	%		56.7	%
QED Therapeutics, Inc.	Controlled VIE	January 2018		96.6	%		94.4	%
Adrenas Therapeutics, Inc.	Controlled VIE	January 2018		88.7	%		90.1	%
Orfan Biotech, Inc.	Controlled VIE	January 2018		89.6	%		85.1	%
Ferro Therapeutics, Inc.	Controlled VIE	March 2018		90.0	%		89.4	%
Origin Biosciences, Inc.	Controlled VIE	April 2018		99.8	%		100	%
Venthera, Inc.	Controlled VIE	April 2018		81.8	%		82.0	%
Aspa Therapeutics, Inc.	Controlled VIE	June 2018		90.3	%		92.5	%

(1)	Subsequent to the Eidos Therapeutics, Inc. (“Eidos”) initial public offering in June 2018 and through June 30, 2019, BridgeBio has a majority voting interest in Eidos and consolidates Eidos under the VOE model. Refer to Note 5.

(2)

Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash

	June 30, 2019		June 30, 2018
	(in thousands)
Cash and cash equivalents	$	293,803	$	252,379
Restricted cash		424		359
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$	294,227	$	252,738

Fair Value Measurement (Tables) - BridgeBio Pharma LLC

6 Months Ended

Jun. 30, 2019

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

	June 30, 2019
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	249,138	$	249,138	$	—	$	—
Total assets	$	249,138	$	249,138	$	—	$	—
Liabilities:
LEO Call Option liability	$	4,297	$	—	$	—	$	4,297
Total liabilities	$	4,297	$	—	$	—	$	4,297

	December 31, 2018
	Total		Level 1		Level 2		Level 3
	(in thousands)
Assets:
Money market funds	$	395,780	$	395,780	$	—	$	—
Total assets	$	395,780	$	395,780	$	—	$	—
Liabilities:
LEO Call Option liability	$	3,009	$	—	$	—	$	3,009
Total liabilities	$	3,009	$	—	$	—	$	3,009

Schedule of Estimated Fair Value of LEO Call Option

	June 30, 2019		December 31, 2018
Probability of milestone achievement	12.0%-84.0%		12.0%-84.0%
Discount rate	1.8%-15.3%		2.7%-11.0%
Expected term (in years)	0.75-4.37		0.58-4.38
Expected volatility	67.5%-78.0%		67.0%-79.0%
Risk-free interest rate	2.92%-3.20%		2.51%-2.78%
Dividend yield		—		—

Summary of Changes in Estimated Fair Value of LEO Call Option

The following table sets forth a summary of the changes in the estimated fair value of the LEO Call Option:

	Total
	(in thousands)
Balance as of December 31, 2018	$	3,009
Change in fair value upon remeasurement recognized in other (income) expense		1,288
Balance as of June 30, 2019	$	4,297

Balance Sheet Components (Tables) - BridgeBio Pharma LLC

6 Months Ended

Jun. 30, 2019

Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Prepaid clinical and research related expenses	$	7,532	$	7,087
Other current assets		5,374		2,050
Total prepaid expenses and other current assets	$	12,906	$	9,137

Summary of Other Accrued Liabilities

Other accrued liabilities consist of the following:

	June 30, 2019		December 31, 2018
	(in thousands)
Accrued professional services	$	3,320	$	772
Accrued other liabilities		868		1,328
Total other accrued liabilities	$	4,188	$	2,100

Variable Interest Entities and Voting Interest Model (Tables)

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Summary of Assets and Liabilities for Consolidated VIEs

The following table provides the assets and liabilities for all consolidated VIEs as of June 30, 2019:

	Adrenas		Aspa		PTR		QED		Venthera		All Other		Total
	(in thousands)
Assets:
Current assets:
Cash and cash equivalents	$	1,912	$	3,697	$	1,704	$	5,579	$	1,957	$	19,364	$	34,213
Prepaid expenses and other current assets		820		843		451		4,502		—		383		6,999
Total current assets		2,732		4,540		2,155		10,081		1,957		19,747		41,212
Property and equipment, net		566		310		76		321		—		290		1,563
Other assets		8		—		1		348		—		—		357
Total assets	$	3,306	$	4,850	$	2,232	$	10,750	$	1,957	$	20,037	$	43,132
Liabilities:
Current liabilities:
Accounts payable	$	1,338	$	1,814	$	420	$	2,625	$	836	$	2,621	$	9,654
Accrued compensation and benefits		278		31		247		1,204		—		750		2,510
Accrued research and development liabilities		82		99		145		3,151		32		2,469		5,978
Other accrued liabilities		171		10		134		267		—		117		699
Total current liabilities		1,869		1,954		946		7,247		868		5,957		18,841
Other liabilities		—		—		—		159		—		24		183
Total liabilities	$	1,869	$	1,954	$	946	$	7,406	$	868	$	5,981	$	19,024

The following table provides the assets and liabilities for all consolidated VIEs as of December 31, 2018:

	Adrenas		Aspa		PTR		QED		Venthera		All Other		Total
	(in thousands)
Assets:
Current assets:
Cash and cash equivalents	$	3,046	$	4,259	$	6,934	$	8,630	$	2,913	$	6,713	$	32,495
Prepaid expenses and other current assets		665		1,722		28		3,240		—		321		5,976
Total current assets		3,711		5,981		6,962		11,870		2,913		7,034		38,471
Property and equipment, net		584		129		88		181		—		277		1,259
Other assets		7		—		41		—		—		28		76
Total assets	$	4,302	$	6,110	$	7,091	$	12,051	$	2,913	$	7,339	$	39,806
Liabilities:
Current liabilities:
Accounts payable	$	1,876	$	1,187	$	621	$	3,537	$	333	$	1,737	$	9,291
Accrued compensation and benefits		377		30		287		1,392		—		467		2,553
Accrued research and development liabilities		227		728		—		4,390		—		1,251		6,596
Other accrued liabilities		28		32		8		229		9		82		388
Total current liabilities		2,508		1,977		916		9,548		342		3,537		18,828
Other liabilities		—		—		—		150		—		29		179
Total liabilities	$	2,508	$	1,977	$	916	$	9,698	$	342	$	3,566	$	19,007

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

Noncontrolling Interests (Tables) - BridgeBio Pharma LLC

6 Months Ended

Jun. 30, 2019

Schedule of Noncontrolling Interests Balance

The following table provides a rollforward of the noncontrolling interests balance:

	Adrenas			Aspa			Eidos			PTR			Venthera			All Other			Total
	(in thousands)
Balance as of December 31, 2018	$	217		$	245		$	58,185		$	2,728		$	449		$	537		$	62,361
Issuance of noncontrolling interest		2			2			1,027			34			1			254			1,320
Transfers to (from) noncontrolling interest		874			472			(337	)		(10	)		(1	)		1,100			2,098
Net loss attributable to noncontrolling interest		(451	)		(222	)		(4,365	)		(1,580	)		(192	)		(651	)		(7,461	)
Balance as of March 31, 2019		642			497			54,510			1,172			257			1,240			58,318
Issuance (repurchase) of noncontrolling interest		3			2			(27,030	)		—			—			1			(27,024	)
Transfers to (from) noncontrolling interest		32			208			23,751			4			273			514			24,782
Net loss attributable to noncontrolling interest		(554	)		(471	)		(5,200	)		(552	)		(353	)		(555	)		(7,685	)
Balance as of June 30, 2019	$	123		$	236		$	46,031		$	624		$	177		$	1,200		$	48,391

Redeemable Convertible Noncontrolling Interests

Schedule of Redeemable Convertible Noncontrolling Interests Balance

The following table provides a rollforward of the redeemable convertible noncontrolling interests balance, as follows:

	Orfan			QED			Total
	(in thousands)
Balance as of December 31, 2018	$	8		$	114		$	122
Net loss attributable to redeemable convertible noncontrolling interest		(34	)		(756	)		(790	)
Transfers to redeemable convertible noncontrolling interest		57			813			870
Balance as of March 31, 2019		31			171			202
Net loss attributable to redeemable convertible noncontrolling interest		(23	)		(662	)		(685	)
Transfers to redeemable convertible noncontrolling interest		47			611			658
Balance as of June 30, 2019	$	55		$	120		$	175

Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units (Tables)

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Temporary Equity [Line Items]

Schedule of Outstanding Preferred Units, Founder Units and Common Units

Outstanding Preferred Units, Founder Units and Common Units consist of the following:

	Units Issued and Outstanding		Original Issue Price Per Unit		Carrying Value		Liquidation Preference
	(in thousands, except unit and per unit amounts)
Series A Preferred Units		24,935,281	$	0.2627	$	4,919	$	13,542
Series B Preferred Units		90,909,090	$	0.4400		39,945		47,096
Series C Preferred Units		141,155,758	$	0.9656		135,482		147,155
Series D Preferred Units		150,955,597	$	1.9823		298,698		299,239
Total Preferred Units as of June 30, 2019		407,955,726				479,044		507,032
Founder Units		11,420,741	$	—		1,754		6,202
Common Units		7,868,637	$	—		1,672		4,274
Total outstanding units as of June 30, 2019		427,245,104			$	482,470	$	517,508

	Units Issued and Outstanding		Original Issue Price Per Unit		Carrying Value		Liquidation Preference
	(in thousands, except unit and per unit amounts)
Series A Preferred Units		24,935,281	$	0.2627	$	4,919	$	13,542
Series B Preferred Units		90,909,090	$	0.4400		39,766		47,096
Series C Preferred Units		141,155,758	$	0.9656		135,482		147,155
Series D Preferred Units		150,955,597	$	1.9823		298,698		299,239
Total Preferred Units as of December 31, 2018		407,955,726				478,865		507,032
Founder Units		11,420,741	$	—		1,754		6,202
Common Units		7,197,783	$	—		1,619		3,910
Total outstanding units as of December 31, 2018		426,574,250			$	482,238	$	517,144

Equity-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2019

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Stock Option Activity

The following table summarizes the Corporation’s stock option activity for the period from May 17, 2019 through June 30, 2019:

	Options Available for Grant			Options Outstanding		Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of May 17, 2019		—			—	$	—		—	$	—
Authorized		11,500,000			—	$	—
Granted		(3,744,629	)		3,744,629	$	17.00
Outstanding as of June 30, 2019		7,755,371			3,744,629	$	17.00		6.02	$	37,334
Exercisable as of June 30, 2019					—	$	—		—	$	—

Summary of Assumptions used to Determine Fair Value of Stock Option Awards Granted to Employees, Directors and Nonemployees

The fair value of each stock option grant was determined by the Corporation at the grant date using a Black-Scholes option-pricing model with the following assumptions:

	May 17, 2019 – June 30, 2019
Expected term (in years)	6.02-6.08
Expected volatility		37.5	%
Risk-free interest rate		1.86	%
Dividend yield		—
Weighted average fair value of share-based awards granted	$	6.64

BridgeBio Pharma LLC

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Equity Based Compensation for Employees and Non Employees

The Company recorded equity-based compensation in the following expense categories in its condensed consolidated statements of operations for employees and non-employees:

	Six Months Ended June 30, 2019
	BridgeBio		Eidos		Other		Total
	(in thousands)
Research and development	$	—	$	1,004	$	19	$	1,023
General and administrative		3,355		1,126		17		4,498
Total equity-based compensation	$	3,355	$	2,130	$	36	$	5,521

	Six Months Ended June 30, 2018
	BridgeBio		Eidos		Other		Total
	(in thousands)
Research and development	$	—	$	620	$	62	$	682
General and administrative		646		386		54		1,086
Total equity-based compensation	$	646	$	1,006	$	116	$	1,768

Summary of Estimated Grant Date Fair Value of Each Common Unit and Management Incentive Unit

The estimated grant-date fair value of each Common Unit and Management Incentive Unit award was calculated using the Black-Scholes option pricing model, based on assumptions as follows:

	Six Months Ended June 30,
	2019		2018
Expected term (in years)		1.50	0.75-1.50
Expected volatility	48.0%-49.0%		40.0%-45.0%
Risk-free interest rate	2.34%-2.56%		1.70%-2.22%
Dividend yield		—		—

Summary of Common Units Activity

The following table summarizes BridgeBio’s Common Units activity:

	Number of Common Units Outstanding		Weighted- Average Grant Date Fair Value
Balance as of December 31, 2018		7,197,783	$	0.08
Vested		670,854	$	0.08
Balance as of June 30, 2019		7,868,637	$	0.08

Summary of Authorized Management Incentive Units Activity

The following table summarizes BridgeBio’s authorized Management Incentive Units activity:

	Number of Authorized Units
Balance as of December 31, 2018		48,695,602
Authorized and granted		24,111,064
Cancelled		(5,000	)
Balance as of June 30, 2019		72,801,666

Summary of Vested Management Incentive Units Activity

The following table summarizes BridgeBio’s vested Management Incentive Units activity:

	Number of Management Incentive Units Outstanding		Weighted- Average Grant Date Fair Value
Balance as of December 31, 2018		19,117,628	$	0.08
Vested		6,460,380	$	0.36
Balance as of June 30, 2019		25,578,008	$	0.14

Eidos Therapeutics, Inc

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Reserved Shares of Common Stock for Issuance

Eidos has reserved shares of common stock for issuance as follows:

	As of June 30,
	2019		2018
Options issued and outstanding		1,454,461		881,612
Options available for future grants		537,345		490,360
Eidos ESPP shares available for future grants		104,540		143,520
Total		2,096,346		1,515,492

Summary of Stock Option Activity

The following table summarizes Eidos’s stock option activity for the six months ended June 30, 2019:

	Options Available for Grant			Options Outstanding			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (years)		Aggregate Intrinsic Value
	(in thousands, except per share and per share data)
Outstanding as of December 31, 2018		747,057			1,329,762		$	8.55		9.40	$	6,928
Granted		(209,712	)		209,712		$	27.22
Exercised		—			(85,013	)	$	1.32
Outstanding as of June 30, 2019		537,345			1,454,461		$	11.66		9.07	$	28,246
Vested and expected to vest as of June 30, 2019					251,447		$	6.26		8.69	$	6,240
Exercisable as of June 30, 2019					1,454,461		$	11.66		9.07	$	28,246

Eidos Therapeutics, Inc | Employee Stock Options Valuation

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Assumptions used to Determine Fair Value of Stock Option Awards Granted to Employees, Directors and Nonemployees

The fair value of employee and non-employee director stock option awards was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions:

	Six Months Ended June 30,
	2019			2018
Expected term (in years)		6.07			6.08
Expected volatility		72.31	%		69.59	%
Risk-free interest rate		2.10	%		2.78	%
Dividend yield		—			—
Weighted average fair value of share-based awards granted	$	18.22		$	7.50

Eidos Therapeutics, Inc | Stock Options Granted To Non-Employees

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Summary of Assumptions used to Determine Fair Value of Stock Option Awards Granted to Employees, Directors and Nonemployees

The fair value of the stock options granted to non-employees was calculated at each reporting date using the Black-Scholes option-pricing model with the following assumptions:

	Six Months Ended June 30,
	2019			2018
Expected term (in years)		6.08			9.70
Expected volatility		73.54	%		68.31	%
Risk-free interest rate		2.74	%		2.84	%
Dividend yield		—			—

Net loss per Unit (Tables)

6 Months Ended

Jun. 30, 2019

BridgeBio Pharma LLC

Schedule of Outstanding Units Excluded from Computation of Diluted Net Loss Per Unit

The following outstanding units were excluded from the computation of the diluted net loss per unit for the periods presented because their effect would have been anti-dilutive.

	June 30,
	2019		2018
Preferred Units		407,955,726		257,000,129
Management Incentive Units		72,801,666		45,678,102
Unvested Common Units		1,229,885		2,571,593
Total		481,987,277		305,249,824

Organization and Background - Additional Information (Details) - shares	6 Months Ended
	Jun. 30, 2019	May 17, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Entity date of incorporation	May 17, 2019
Entity incorporation, state	Delaware
Common stock, outstanding	0	0

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Summary Of Significant Accounting Policies [Line Items]
Stock awards, vesting period	4 years
Cash and cash equivalents	$ 112,400,000	$ 238,700,000
BridgeBio Pharma LLC
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 400,000	$ 200,000
Restricted Cash, Noncurrent, Asset, Statement of Financial Position [Extensible List]	us-gaap:OtherNoncurrentAssetsMember	us-gaap:OtherNoncurrentAssetsMember
Cash and cash equivalents	$ 293,803,000	$ 436,086,000	$ 252,379,000
BridgeBio Pharma LLC \| Other Assets
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs	$ 6,500,000	$ 0
Minimum
Summary Of Significant Accounting Policies [Line Items]
Percentage of voting shares	50.00%

Stockholders' Deficit - Additional Information (Details) - $ / shares	Jun. 30, 2019	Jun. 26, 2019	May 17, 2019
Equity [Abstract]
Common stock, shares authorized	500,000,000	500,000,000	1,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000	0
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares issued	0		0
Common stock, outstanding	0		0
Preferred stock, shares issued	0		0
Preferred stock, shares outstanding	0		0

Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions					1 Months Ended	6 Months Ended
	Jun. 26, 2019	Jun. 25, 2019	Jun. 22, 2019	Jun. 21, 2019	Jun. 30, 2019	Jun. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of options						4 years
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares initially reserved for issuance of awards			2,000,000
Employee stock purchase plan effective date			Jun. 25, 2019
Effective date from which automatic annual increase in number of shares reserved for future issuance			Jan. 01, 2020
Percentage of automatic annual increase in number of shares reserved for future issuance			1.00%
Shares issued					0
Shares outstanding					0	0
2019 Employee Stock Purchase Plan \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares initially reserved for issuance of awards			2,000,000
2019 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in number of shares reserved and available for issuance in proportion to common stock outstanding, annual increase date		--01-01
Increase in number of shares reserved and available for issuance in proportion to common stock outstanding, starting date		Jan. 01, 2020
Percentage of increase in number of shares reserved and available for issuance in proportion to common stock outstanding		5.00%
Grant of options to purchase shares	48,200			3,696,429	3,744,629
Exercise price on grant of options to purchase shares				$ 17.00	$ 17.00
Vesting period of options	4 years
Unrecognized compensation cost related to unvested equity-based compensation arrangements					$ 24.8	$ 24.8
Unrecognized compensation cost related to unvested equity-based compensation arrangements, period for recognition						4 years
2019 Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of common shares initially reserved for issuance of awards		11,500,000

Stock-based Compensation - Summary of Stock Option Activity (Details) - 2019 Plan $ / shares in Units, $ in Thousands			1 Months Ended
	Jun. 26, 2019 shares	Jun. 21, 2019 $ / shares shares	Jun. 30, 2019 USD ($) $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Available for Grant, Authorized			11,500,000
Options Available for Grant, Granted			(3,744,629)
Options Available for Grant, Outstanding, Ending balance			7,755,371
Options Outstanding, Granted	48,200	3,696,429	3,744,629
Options Outstanding, Outstanding, Ending balance			3,744,629
Weighted-Average Exercise Price per Option, Granted \| $ / shares		$ 17.00	$ 17.00
Weighted-Average Exercise Price per Option, Outstanding, Ending balance \| $ / shares			$ 17.00
Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance			6 years 7 days
Weighted-Average Remaining Contractual Life (years), Exercisable as of June 30, 2019			0 years
Aggregate Intrinsic Value, Outstanding, Ending balance \| $			$ 37,334

Stock-based Compensation - Summary of Assumptions used to Determine the Fair Value of Stock Option Awards Granted to Employees, Directors and Nonemployees (Details)	1 Months Ended
	Jun. 30, 2019 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	37.50%
Risk-free interest rate	1.86%
Weighted average fair value of share-based awards granted	$ 6.64
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 7 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 29 days

Subsequent Events - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	6 Months Ended
	Aug. 13, 2019	Jul. 01, 2019	Jul. 31, 2019	Jun. 30, 2019	Aug. 08, 2019	May 17, 2019
Subsequent Event [Line Items]
Purchase of common stock, shares				0		0
Common stock, value				$ 0		$ 0
BridgeBio Pharma LLC
Subsequent Event [Line Items]
Debt instrument interest only extension date				Jul. 01, 2021
Debt instrument maturity date extension				Jan. 01, 2023
Subsequent Event
Subsequent Event [Line Items]
Net proceeds from IPO, after deducting underwriters’ discounts and commissions		$ 366,300
Subsequent Event \| BridgeBio Pharma LLC
Subsequent Event [Line Items]
Payment in kind, interest rate		83.33%
Subsequent Event \| BridgeBio Pharma LLC \| Maximum \| Payment in Kind
Subsequent Event [Line Items]
Cash payment interest		1.50%
Subsequent Event \| BridgeBio Pharma LLC \| Tranches I
Subsequent Event [Line Items]
Reduction on the effective interest rate		0.50%
Subsequent Event \| BridgeBio Pharma LLC \| Tranches II
Subsequent Event [Line Items]
Reduction on the effective interest rate		0.50%
Subsequent Event \| QED Therapeutics, Inc
Subsequent Event [Line Items]
Investments	$ 40,000
Subsequent Event \| Phoenix Tissue Repair, Inc (“PTR”)
Subsequent Event [Line Items]
Investments	7,000
Subsequent Event \| Aspa Therapeutics, Inc
Subsequent Event [Line Items]
Investments	3,600
Subsequent Event \| Adrenas Therapeutics, Inc
Subsequent Event [Line Items]
Investments	3,600
Subsequent Event \| Fortify Therapeutics Inc
Subsequent Event [Line Items]
Investments	$ 1,500
Subsequent Event \| Eidos \| BridgeBio Pharma LLC
Subsequent Event [Line Items]
Purchase of common stock, shares			882,353
Common stock, value			$ 26,400
Subsequent Event \| Biopharmaceutical Entity
Subsequent Event [Line Items]
Purchase of preferred stock			7,000
Subsequent Event \| Biopharmaceutical Entity \| Maximum
Subsequent Event [Line Items]
Preferred stock option to purchase additional shares			$ 24,500
Subsequent Event \| Common Stock
Subsequent Event [Line Items]
Net proceeds from IPO, after deducting underwriters’ discounts and commissions		$ 366,300
Underwriters' discounts and commissions		28,000
Deferred offering costs		6,500
Subsequent Event \| Common Stock \| BridgeBio Pharma LLC
Subsequent Event [Line Items]
Deferred offering costs		$ 6,500
Subsequent Event \| Common Stock \| Eidos
Subsequent Event [Line Items]
Fixed exchange ratio					1.30%
Subsequent Event \| Initial Public Offering \| Common Stock
Subsequent Event [Line Items]
Sale of stock, number of shares issued and sold		23,575,000
Sale of stock, public offering price per share		$ 17.00
Subsequent Event \| Initial Public Offering \| Common Stock \| BridgeBio Pharma LLC
Subsequent Event [Line Items]
Sale of stock, number of shares issued and sold		23,575,000
Sale of stock, public offering price per share		$ 17.00
Underwriters' discounts and commissions		$ 28,000
Net proceeds from issuance initial public offering after deducting underwriters' discounts and commissions and offering costs		$ 366,300
Subsequent Event \| Over-Allotment Option \| Common Stock
Subsequent Event [Line Items]
Sale of stock, number of shares issued and sold		3,075,000
Subsequent Event \| Over-Allotment Option \| Common Stock \| BridgeBio Pharma LLC
Subsequent Event [Line Items]
Sale of stock, number of shares issued and sold		3,075,000

Subsequent Events - Summary of Outstanding Units Class of BridgeBio Pharma, LLC Cancelled and Exchanged for Shares of Common Stock Upon Reorganization (Details) - BridgeBio Pharma LLC - Subsequent Event	Jul. 01, 2019 shares
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	99,999,967
Series D Preferred Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	30,459,426
Series C Preferred Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	31,992,709
Series B Preferred Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	17,794,455
Series A Preferred Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	4,918,881
Founder Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	2,252,916
Common Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	1,794,823
Management Incentive Units
Subsequent Event [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	10,786,757

Organization and Description of Business - Additional Information (Details) - USD ($) $ in Thousands	Jul. 01, 2019	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Organization And Description Of Business [Line Items]
Accumulated deficit		$ 69
Cash and cash equivalents		112,400	$ 238,700
Subsequent Event
Organization And Description Of Business [Line Items]
Net proceeds received from the completion of the IPO	$ 366,300
BridgeBio Pharma LLC
Organization And Description Of Business [Line Items]
Accumulated deficit		326,068	170,580
Cash and cash equivalents		$ 293,803	$ 436,086	$ 252,379

Summary of Significant Accounting Policies - Summary of Investments (Details) - BridgeBio Pharma LLC	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
TheRas, Inc \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2016-08
Ownership %	100.00%	100.00%
BridgeBio Services, Inc \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2017-04
Ownership %	100.00%	100.00%
Origin Biosciences, Inc. \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-04
Ownership %	99.80%	100.00%
Fortify Therapeutics Inc \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-06
Ownership %	100.00%	100.00%
Sub20, Inc \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-06
Ownership %	100.00%	100.00%
Unnamed Entity 1 \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-12
Ownership %	100.00%	100.00%
Unnamed Entity 2 \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2019-04
Ownership %	100.00%
Unnamed Entity 3 \| Wholly-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2019-05
Ownership %	100.00%
Eidos Therapeutics, Inc \| Partially-owned Subsidiary
Variable Interest Entity [Line Items]
Date Control First Acquired	2016-04
Ownership %	65.10%	62.50%
Molecular Skin Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2016-07
Ownership %	58.20%	61.70%
Quartz Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2016-10
Ownership %	89.00%	89.00%
PellePharm, Inc \| VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2016-12
Ownership %	43.30%	43.30%
Navire Pharma, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2017-02
Ownership %	78.90%	78.80%
CoA Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2017-02
Ownership %	99.60%	99.50%
Dermecular Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2017-04
Ownership %	87.60%	87.60%
Phoenix Tissue Repair, Inc (“PTR”) \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2017-07
Ownership %	56.40%	56.70%
QED Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-01
Ownership %	96.60%	94.40%
Adrenas Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-01
Ownership %	88.70%	90.10%
Orfan Biotech, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-01
Ownership %	89.60%	85.10%
Ferro Therapeutics, Inc. \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-03
Ownership %	90.00%	89.40%
Aspa Therapeutics, Inc \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-06
Ownership %	90.30%	92.50%
Venthera, Inc. \| Controlled VIE
Variable Interest Entity [Line Items]
Date Control First Acquired	2018-04
Ownership %	81.80%	82.00%

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Line Items]
Cash and cash equivalents	$ 112,400	$ 238,700
BridgeBio Pharma LLC
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Line Items]
Cash and cash equivalents	293,803	436,086	$ 252,379
Restricted cash	424		359
Total cash, cash equivalents and restricted cash shown in the condensed consolidated statements of cash flows	$ 294,227	$ 436,245	$ 252,738	$ 92,376

Fair Value Measurement - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - BridgeBio Pharma LLC - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Liabilities:
LEO Call Option liability	$ 4,297	$ 3,009
Recurring
Assets:
Money market funds	249,138	395,780
Total assets	249,138	395,780
Liabilities:
LEO Call Option liability	4,297	3,009
Total liabilities	4,297	3,009
Recurring \| Level 1
Assets:
Money market funds	249,138	395,780
Total assets	249,138	395,780
Recurring \| Level 3
Liabilities:
LEO Call Option liability	4,297	3,009
Total liabilities	$ 4,297	$ 3,009

Fair Value Measurement - Additional Information (Details) - BridgeBio Pharma LLC - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value financial assets, outside of cash and cash equivalents	$ 0	$ 0
Fair value assets, transfers between Level 1, Level 2 or Level 3	0	0
Fair value liabilities, transfers between Level 1, Level 2 or Level 3	$ 0	$ 0

Fair Value Measurement - Schedule of Estimated Fair Value of LEO Call Option (Details) - BridgeBio Pharma LLC	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	9 months	6 months 29 days
Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	4 years 4 months 13 days	4 years 4 months 17 days
Probability of Milestone Achievement \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	12.0	12.0
Probability of Milestone Achievement \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	84.0	84.0
Discount Rate \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	1.8	2.7
Discount Rate \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	15.3	11.0
Expected Volatility \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	67.5	67.0
Expected Volatility \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	78.0	79.0
Risk-Free Interest Rate \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	2.92	2.51
Risk-Free Interest Rate \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	3.20	2.78

Fair Value Measurement - Summary of Changes in Estimated Fair Value of LEO Call Option (Details) - BridgeBio Pharma LLC $ in Thousands	6 Months Ended
	Jun. 30, 2019 USD ($)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance	$ 3,009
Change in fair value upon remeasurement recognized in other (income) expense	1,288
Ending balance	$ 4,297

Balance Sheet Components - Summary of Prepaid Expenses and Other Current Assets (Details) - BridgeBio Pharma LLC - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Balance Sheet Components [Line Items]
Prepaid clinical and research related expenses	$ 7,532	$ 7,087
Other current assets	5,374	2,050
Total prepaid expenses and other current assets	$ 12,906	$ 9,137

Balance Sheet Components - Summary of Other Accrued Liabilities (Details) - BridgeBio Pharma LLC - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Balance Sheet Components [Line Items]
Accrued professional services	$ 3,320	$ 772
Accrued other liabilities	868	1,328
Total other accrued liabilities	$ 4,188	$ 2,100

Variable Interest Entities and Voting Interest Model - Additional Information (Details) - BridgeBio Pharma LLC - Variable Interest Entity, Primary Beneficiary - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	May 31, 2019	Jun. 30, 2019
Eidos
Variable Interest Entity [Line Items]
Voting shares		50.00%
Purchase of common stock, shares	1,103,848
Common stock, value	$ 28.6
QED Therapeutics, Inc
Variable Interest Entity [Line Items]
Investments		$ 40.0
Quartz Therapeutics, Inc
Variable Interest Entity [Line Items]
Investments		0.4
CoA Therapeutics, Inc
Variable Interest Entity [Line Items]
Investments		5.1
Orfan Biotech, Inc
Variable Interest Entity [Line Items]
Investments		3.5
Ferro Therapeutics, Inc.
Variable Interest Entity [Line Items]
Investments		4.5
Aspa Therapeutics, Inc
Variable Interest Entity [Line Items]
Investments		8.0
Adrenas Therapeutics, Inc
Variable Interest Entity [Line Items]
Investments		8.0
Origin Biosciences, Inc.
Variable Interest Entity [Line Items]
Investments		10.0
Venthera, Inc.
Variable Interest Entity [Line Items]
Investments		1.5
Navire Pharma, Inc
Variable Interest Entity [Line Items]
Investments		$ 4.5

Variable Interest Entities and Voting Interest Model - Summary of Assets and Liabilities for Consolidated VIEs (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 112,400	$ 238,700
BridgeBio Pharma LLC
Current assets:
Cash and cash equivalents	293,803	436,086	$ 252,379
Prepaid expenses and other current assets	12,906	9,137
Total current assets	306,709	445,223
Property and equipment, net	1,865	1,575
Other assets	9,471	1,093
Total assets	325,540	464,941
Current liabilities:
Accounts payable	16,065	13,509
Accrued research and development liabilities	9,419	8,915
Accrued other liabilities	868	1,328
Total current liabilities	38,705	32,577
Other liabilities	347	495
Total liabilities	114,049	87,579
BridgeBio Pharma LLC \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	34,213	32,495
Prepaid expenses and other current assets	6,999	5,976
Total current assets	41,212	38,471
Property and equipment, net	1,563	1,259
Other assets	357	76
Total assets	43,132	39,806
Current liabilities:
Accounts payable	9,654	9,291
Accrued compensation and benefits	2,510	2,553
Accrued research and development liabilities	5,978	6,596
Accrued other liabilities	699	388
Total current liabilities	18,841	18,828
Other liabilities	183	179
Total liabilities	19,024	19,007
BridgeBio Pharma LLC \| Adrenas \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	1,912	3,046
Prepaid expenses and other current assets	820	665
Total current assets	2,732	3,711
Property and equipment, net	566	584
Other assets	8	7
Total assets	3,306	4,302
Current liabilities:
Accounts payable	1,338	1,876
Accrued compensation and benefits	278	377
Accrued research and development liabilities	82	227
Accrued other liabilities	171	28
Total current liabilities	1,869	2,508
Total liabilities	1,869	2,508
BridgeBio Pharma LLC \| Aspa \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	3,697	4,259
Prepaid expenses and other current assets	843	1,722
Total current assets	4,540	5,981
Property and equipment, net	310	129
Total assets	4,850	6,110
Current liabilities:
Accounts payable	1,814	1,187
Accrued compensation and benefits	31	30
Accrued research and development liabilities	99	728
Accrued other liabilities	10	32
Total current liabilities	1,954	1,977
Total liabilities	1,954	1,977
BridgeBio Pharma LLC \| PTR \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	1,704	6,934
Prepaid expenses and other current assets	451	28
Total current assets	2,155	6,962
Property and equipment, net	76	88
Other assets	1	41
Total assets	2,232	7,091
Current liabilities:
Accounts payable	420	621
Accrued compensation and benefits	247	287
Accrued research and development liabilities	145
Accrued other liabilities	134	8
Total current liabilities	946	916
Total liabilities	946	916
BridgeBio Pharma LLC \| QED \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	5,579	8,630
Prepaid expenses and other current assets	4,502	3,240
Total current assets	10,081	11,870
Property and equipment, net	321	181
Other assets	348
Total assets	10,750	12,051
Current liabilities:
Accounts payable	2,625	3,537
Accrued compensation and benefits	1,204	1,392
Accrued research and development liabilities	3,151	4,390
Accrued other liabilities	267	229
Total current liabilities	7,247	9,548
Other liabilities	159	150
Total liabilities	7,406	9,698
BridgeBio Pharma LLC \| Venthera \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	1,957	2,913
Total current assets	1,957	2,913
Total assets	1,957	2,913
Current liabilities:
Accounts payable	836	333
Accrued research and development liabilities	32
Accrued other liabilities		9
Total current liabilities	868	342
Total liabilities	868	342
BridgeBio Pharma LLC \| All Other \| Variable Interest Entity, Primary Beneficiary
Current assets:
Cash and cash equivalents	19,364	6,713
Prepaid expenses and other current assets	383	321
Total current assets	19,747	7,034
Property and equipment, net	290	277
Other assets		28
Total assets	20,037	7,339
Current liabilities:
Accounts payable	2,621	1,737
Accrued compensation and benefits	750	467
Accrued research and development liabilities	2,469	1,251
Accrued other liabilities	117	82
Total current liabilities	5,957	3,537
Other liabilities	24	29
Total liabilities	$ 5,981	$ 3,566

Noncontrolling Interests - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
BridgeBio Pharma LLC
Redeemable Noncontrolling Interest [Line Items]
Adjustments of Carrying Value of Noncontrolling Interest to Accumulated Deficit	$ 25.4	$ 56.2	$ 28.4	$ 60.1

Noncontrolling Interests - Schedule of Redeemable Convertible Noncontrolling Interests Balance (Details) - Redeemable Convertible Noncontrolling Interests - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018
Orfan Biotech, Inc
Redeemable Noncontrolling Interest [Line Items]
Temporary equity, beginning balance	$ 31	$ 8
Net loss attributable to redeemable convertible noncontrolling interest	(23)	(34)
Transfers to (from) noncontrolling interest	47	57
Temporary equity, ending balance	55	31
QED Therapeutics, Inc
Redeemable Noncontrolling Interest [Line Items]
Temporary equity, beginning balance	171	114
Net loss attributable to redeemable convertible noncontrolling interest	(662)	(756)
Transfers to (from) noncontrolling interest	611	813
Temporary equity, ending balance	120	171
BridgeBio Pharma LLC
Redeemable Noncontrolling Interest [Line Items]
Temporary equity, beginning balance	202	122	$ 1,550	$ 833
Net loss attributable to redeemable convertible noncontrolling interest	(685)	(790)
Transfers to (from) noncontrolling interest	658	870	(41,450)	(11,286)
Temporary equity, ending balance	$ 175	$ 202	$ 3,192	$ 1,550

Noncontrolling Interests - Schedule of Noncontrolling Interests Balance (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018
Adrenas Therapeutics, Inc
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		$ 217			$ 217
Issuance of noncontrolling interest		2
Issuance (repurchase) of noncontrolling interest	$ 3
Transfers to (from) noncontrolling interest (Note 6)	32	874
Net loss attributable to noncontrolling interest	(554)	(451)
Noncontrolling interests, ending balance		642
Noncontrolling interests, ending balance	123				123
Aspa Therapeutics, Inc
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		245			245
Issuance of noncontrolling interest		2
Issuance (repurchase) of noncontrolling interest	2
Transfers to (from) noncontrolling interest (Note 6)	208	472
Net loss attributable to noncontrolling interest	(471)	(222)
Noncontrolling interests, ending balance		497
Noncontrolling interests, ending balance	236				236
Eidos Therapeutics, Inc
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		58,185			58,185
Issuance of noncontrolling interest		1,027
Issuance (repurchase) of noncontrolling interest	(27,030)
Transfers to (from) noncontrolling interest (Note 6)	23,751	(337)
Net loss attributable to noncontrolling interest	(5,200)	(4,365)
Noncontrolling interests, ending balance		54,510
Noncontrolling interests, ending balance	46,031				46,031
Phoenix Tissue Repair, Inc (“PTR”)
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		2,728			2,728
Issuance of noncontrolling interest		34
Transfers to (from) noncontrolling interest (Note 6)	4	(10)
Net loss attributable to noncontrolling interest	(552)	(1,580)
Noncontrolling interests, ending balance		1,172
Noncontrolling interests, ending balance	624				624
Venthera, Inc.
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		449			449
Issuance of noncontrolling interest		1
Transfers to (from) noncontrolling interest (Note 6)	273	(1)
Net loss attributable to noncontrolling interest	(353)	(192)
Noncontrolling interests, ending balance		257
Noncontrolling interests, ending balance	177				177
All Other
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		537			537
Issuance of noncontrolling interest		254
Issuance (repurchase) of noncontrolling interest	1
Transfers to (from) noncontrolling interest (Note 6)	514	1,100
Net loss attributable to noncontrolling interest	(555)	(651)
Noncontrolling interests, ending balance		1,240
Noncontrolling interests, ending balance	1,200				1,200
BridgeBio Pharma LLC
Minority Interest [Line Items]
Noncontrolling interests, beginning balance		62,361			62,361
Issuance of noncontrolling interest		1,320
Issuance (repurchase) of noncontrolling interest	(27,024)	1,320	$ 96,689	$ 553
Transfers to (from) noncontrolling interest (Note 6)	24,782	2,098			28,408	$ 60,058
Net loss attributable to noncontrolling interest	(7,685)	(7,461)
Noncontrolling interests, ending balance		$ 58,318
Noncontrolling interests, ending balance	$ 48,391				$ 48,391

PellePharm Investment - Additional Information (Detail) - PellePharm, Inc - USD ($) $ in Thousands	6 Months Ended	18 Months Ended
	Jun. 30, 2019	Dec. 31, 2016	Mar. 31, 2019	Dec. 31, 2018	Jul. 31, 2015
Schedule Of Investments [Line Items]
Initial investment					$ 4,500
Equity method investment	$ 0		$ 0	$ 200
Cost method investment	$ 7,500			$ 16,800
Preferred stock ownership percentage	62.00%
Minimum
Schedule Of Investments [Line Items]
Ownership interest percentage		50.00%

Hercules Term Loan - Additional Information (Details) - Hercules Capital, Inc - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	6 Months Ended
	Dec. 31, 2018	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2019	May 31, 2019
Debt Instrument [Line Items]
Interest expense			$ 1,900	$ 3,600
Amortization of debt discount			$ 300	$ 700
Tranche II
Debt Instrument [Line Items]
Debt Instrument face amount	$ 20,000
Maturity date	Jul. 01, 2022
Debt instrument, frequency of interest payment				payable monthly
Debt instrument, principal outstanding	$ 55,000
Tranche III
Debt Instrument [Line Items]
Debt Instrument face amount					$ 20,000
Debt instrument, frequency of interest payment				payable monthly
Debt instrument, principal outstanding					$ 75,000
Prime Rate \| Tranche II
Debt Instrument [Line Items]
Interest rate				3.35%
Effective interest rate			9.10%	9.10%
Prime Rate \| Tranche III
Debt Instrument [Line Items]
Interest rate				3.10%
Effective interest rate			9.10%	9.10%
BridgeBio Pharma LLC \| Tranche I
Debt Instrument [Line Items]
Debt Instrument face amount		$ 35,000
Maturity period		42 months
Maturity date		Jan. 01, 2022
Debt instrument, principal payments		$ 0
Effective interest rate			9.35%	9.35%
Debt instrument, frequency of interest payment				payable monthly
BridgeBio Pharma LLC \| Prime Rate \| Tranche I
Debt Instrument [Line Items]
Interest rate				4.35%
Effective interest rate			9.85%	9.85%

License Agreements - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
The University of Texas License Agreement \| Board of Regents \| Navire Pharma, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense	$ 0	$ 200,000
Additional research and development expense	500,000	1,000,000
Leidos Biomedical Research License and Cooperative Research and Development Agreements \| Leidos Biomedical Research, Inc \| TheRas, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense	400,000	600,000
St Jude License Agreement \| St. Jude Children’s Research Hospital, Inc \| CoA Therapeutics, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense	200,000	300,000
Memorial Sloan Kettering Cancer License Agreement \| Memorial Sloan Kettering Cancer Center \| Venthera, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expense	0	0
Life License Agreement \| Life Technologies Corporation \| Aspa
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expense	400,000	400,000
Eidos Therapeutics, Inc \| Stanford License Agreement \| Leland Stanford Junior University
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense	0	200,000
Unnamed Entity \| Unnamed Entity License Agreement \| Unnamed Entitys Drug Discovery And Development Initiatives
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement expense	0	0
QED Therapeutics, Inc \| Foundation Medicine Diagnostics Agreement \| Foundation Medicine, Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expense	$ 300,000	$ 300,000

Asset Acquisitions - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jul. 31, 2017	Jun. 30, 2019	Jun. 30, 2019
Unnamed Entity 2
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Percentage of equity acquired	100.00%
Unnamed Entity 2 \| In Process Research and Development
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Milestone payment method	$ 500,000
Unnamed Entity 2 \| Maximum
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Regulatory milestone payments	7,000,000
Sales milestone payments	$ 65,000,000
Phoenix Tissue Repair, Inc (“PTR”)
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Regulatory milestone payments				$ 25,000,000
Sales milestone payments				60,000,000
Asset acquisition cash payment		$ 1,500,000
Asset acquisition issuance of share		10,019,900
Phoenix Tissue Repair, Inc (“PTR”) \| In Process Research and Development
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Milestone payment method			$ 0	$ 2,000,000

Related Party Transactions - Additional Information (Details) - BridgeBio Pharma LLC - Nonrecourse Notes - Two Founders $ in Millions	6 Months Ended
	Jun. 30, 2019 USD ($)
Related Party Transaction [Line Items]
Debt Instrument face amount	$ 0.3
Maturity date	May 31, 2021
Repayment date	Feb. 28, 2019

Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units - Schedule of Outstanding Preferred Units, Founder Units and Common Units (Details) - BridgeBio Pharma LLC - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	427,245,104	426,574,250
Temporary equity, carrying value	$ 482,470	$ 482,238
Temporary equity, liquidation preference	$ 517,508	$ 517,144
Series A Preferred Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	24,935,281	24,935,281
Temporary equity, original issue price per unit	$ 0.2627	$ 0.2627
Temporary equity, carrying value	$ 4,919	$ 4,919
Temporary equity, liquidation preference	$ 13,542	$ 13,542
Series B Preferred Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	90,909,090	90,909,090
Temporary equity, original issue price per unit	$ 0.4400	$ 0.4400
Temporary equity, carrying value	$ 39,945	$ 39,766
Temporary equity, liquidation preference	$ 47,096	$ 47,096
Series C Preferred Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	141,155,758	141,155,758
Temporary equity, original issue price per unit	$ 0.9656	$ 0.9656
Temporary equity, carrying value	$ 135,482	$ 135,482
Temporary equity, liquidation preference	$ 147,155	$ 147,155
Series D Preferred Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	150,955,597	150,955,597
Temporary equity, original issue price per unit	$ 1.9823	$ 1.9823
Temporary equity, carrying value	$ 298,698	$ 298,698
Temporary equity, liquidation preference	$ 299,239	$ 299,239
Preferred Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	407,955,726	407,955,726
Temporary equity, carrying value	$ 479,044	$ 478,865
Temporary equity, liquidation preference	$ 507,032	$ 507,032
Founder Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	11,420,741	11,420,741
Temporary equity, carrying value	$ 1,754	$ 1,754
Temporary equity, liquidation preference	$ 6,202	$ 6,202
Common Units
Temporary Equity [Line Items]
Temporary equity, units issued and outstanding	7,868,637	7,197,783
Temporary equity, carrying value	$ 1,672	$ 1,619
Temporary equity, liquidation preference	$ 4,274	$ 3,910

Redeemable Convertible Preferred Units, Founder Units, Common Units and Management Incentive Units - Additional Information (Details) - BridgeBio Pharma LLC - USD ($) $ in Millions				1 Months Ended	12 Months Ended
	Jul. 01, 2019	Jun. 30, 2017	Apr. 30, 2015	Feb. 28, 2019	Dec. 31, 2016
Temporary Equity [Line Items]
Payments to acquired equity interest			$ 1.0
Gain on disposal recognized					$ 1.2
Distribution to members		$ 1.2
Accrued distributions		$ 1.0
Accrued distributions paid to unit holders				$ 1.0
Subsequent Event
Temporary Equity [Line Items]
Number of BridgeBio Pharma, Inc. shares issued	99,999,967

Equity-Based Compensation - Summary of Equity Based Compensation for Employees and Non Employees (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	$ 5,521	$ 1,768
BridgeBio Pharma LLC
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	3,355	646
Eidos
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	2,130	1,006
Other
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	36	116
Research and Development Expense
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	1,023	682
Research and Development Expense \| Eidos
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	1,004	620
Research and Development Expense \| Other
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	19	62
General and Administrative
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	4,498	1,086
General and Administrative \| BridgeBio Pharma LLC
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	3,355	646
General and Administrative \| Eidos
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	1,126	386
General and Administrative \| Other
Employee And Non Employee Service Share Based Compensation [Line Items]
Total equity-based compensation	$ 17	$ 54

Equity-Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation			$ 5,521,000	$ 1,768,000
2016 and 2018 Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation cost related to unvested stock	$ 12,500,000		$ 12,500,000
Unrecognized compensation cost related to unvested equity-based compensation arrangements, period for recognition			2 years 7 months 28 days
BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation			$ 3,355,000	646,000
Eidos Therapeutics, Inc
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation			$ 2,130,000	1,006,000
Options Outstanding, Granted			209,712
Eidos Therapeutics, Inc \| Stock Options Granted To Non-Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation	$ 100,000	$ 100,000	$ 100,000	$ 200,000
Options Outstanding, Granted	0	35,880	18,500	35,880
Common Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested units	1,229,885		1,229,885
Unrecognized compensation cost related to unvested equity-based compensation arrangements	$ 100,000		$ 100,000
Weighted average period of unvested units expected to be recognized			10 months 24 days
Unvested units vesting month and year			2020-05
Common Units \| BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized	9,098,522		9,098,522		9,098,522
Common Units \| BridgeBio Pharma LLC \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation	$ 100,000	$ 100,000	$ 100,000	$ 100,000
Management Incentive Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested units	47,223,658		47,223,658
Unrecognized compensation cost related to unvested equity-based compensation arrangements	$ 30,100,000		$ 30,100,000
Weighted average period of unvested units expected to be recognized			4 years
Unvested units vesting month and year			2024-02
Management Incentive Units \| BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Equity-based compensation	$ 2,100,000	$ 300,000	$ 3,300,000	$ 600,000

Equity-Based Compensation - Summary of Estimated Grant Date Fair Value of Each Common Unit and Management Incentive Unit (Details)	1 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Common Unit and Management Incentive Unit Award \| BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		1 year 6 months
Expected volatility, Minimum		48.00%	40.00%
Expected volatility, Maximum		49.00%	45.00%
Risk-free interest rate, Minimum		2.34%	1.70%
Risk-free interest rate, Maximum		2.56%	2.22%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 7 days
Minimum \| Common Unit and Management Incentive Unit Award \| BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			9 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 29 days
Maximum \| Common Unit and Management Incentive Unit Award \| BridgeBio Pharma LLC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)			1 year 6 months

Equity-Based Compensation - Summary of Common Units Activity (Details) - Common Units - BridgeBio Pharma LLC	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance, Number of units outstanding \| shares	7,197,783
Vested, Number of units outstanding \| shares	670,854
Ending balance, Number of units outstanding \| shares	7,868,637
Beginning balance, Weighted average grant date fair value \| $ / shares	$ 0.08
Vested, Weighted average grant date fair value \| $ / shares	0.08
Ending balance, weighted average grant date fair value \| $ / shares	$ 0.08

Equity-Based Compensation - Summary of Authorized Management Incentive Units Activity (Details) - Management Incentive Units - BridgeBio Pharma LLC	6 Months Ended
	Jun. 30, 2019 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance, Number of authorized units	48,695,602
Authorized and granted, Number of authorized units	24,111,064
Cancelled, Number of authorized units	(5,000)
Ending balance, Number of authorized units	72,801,666

Equity-Based Compensation - Summary of Vested Management Incentive Units Activity (Details) - Management Incentive Units - BridgeBio Pharma LLC	6 Months Ended
	Jun. 30, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Beginning balance, Number of units outstanding \| shares	19,117,628
Vested, Number of units outstanding \| shares	6,460,380
Ending balance, Number of units outstanding \| shares	25,578,008
Beginning balance, Weighted average grant date fair value \| $ / shares	$ 0.08
Vested, Weighted average grant date fair value \| $ / shares	0.36
Ending balance, weighted average grant date fair value \| $ / shares	$ 0.14

Equity-Based Compensation - Summary of Reserved Shares of Common Stock for Issuance (Details) - Eidos Therapeutics, Inc - shares	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	2,096,346	1,515,492
Eidos ESPP shares available for future grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	104,540	143,520
Options Issued and Outstanding
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	1,454,461	881,612
Options Available for Future Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for issuance	537,345	490,360

Equity-Based Compensation - Summary of Stock Option Activity (Details) - Eidos Therapeutics, Inc - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options Available for Grant, Outstanding, Beginning balance	747,057
Options Available for Grant, Granted	(209,712)
Options Available for Grant, Outstanding, Ending balance	537,345	747,057
Options Outstanding, Outstanding, Beginning balance	1,329,762
Options Outstanding, Granted	209,712
Options Outstanding, Exercised	(85,013)
Options Outstanding, Outstanding, Ending balance	1,454,461	1,329,762
Options Outstanding, Vested and expected to vest	251,447
Options Outstanding, Exercisable as of June 30, 2019	1,454,461
Weighted-Average Exercise Price per Option, Outstanding, Beginning balance	$ 8.55
Weighted-Average Exercise Price per Option, Granted	27.22
Weighted-Average Exercise Price per Option, Exercised	1.32
Weighted-Average Exercise Price per Option, Outstanding, Ending balance	11.66	$ 8.55
Weighted-Average Exercise Price per Option, Vested and expected to vest	6.26
Weighted-Average Exercise Price per Option, Exercisable	$ 11.66
Weighted-Average Remaining Contractual Life (years), Outstanding, Ending balance	9 years 25 days	9 years 4 months 24 days
Weighted-Average Remaining Contractual Life (years), Exercisable as of June 30, 2019	8 years 8 months 8 days
Weighted-Average Remaining Contractual Life (years), Exercisable	9 years 25 days
Aggregate Intrinsic Value, Outstanding, Ending balance	$ 28,246	$ 6,928
Aggregate Intrinsic Value, Exercisable as of June 30, 2019	6,240
Aggregate Intrinsic Value, Exercisable	$ 28,246

Equity-Based Compensation - Summary of Fair Value of Employee and Non-employee Stock Options Granted (Details) - $ / shares	1 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jun. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility	37.50%
Risk-free interest rate	1.86%
Weighted average fair value of share-based awards granted	$ 6.64
Eidos Therapeutics, Inc \| Employee Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 21 days	6 years 29 days
Expected volatility		72.31%	69.59%
Risk-free interest rate		2.10%	2.78%
Weighted average fair value of share-based awards granted		$ 18.22	$ 7.50
Eidos Therapeutics, Inc \| Stock Options Granted To Non-Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 29 days	9 years 8 months 12 days
Expected volatility		73.54%	68.31%
Risk-free interest rate		2.74%	2.84%

Net loss per Unit - Schedule of Outstanding Units Excluded from Computation of Diluted Net Loss Per Unit (Detail) - BridgeBio Pharma LLC - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Preferred Units	481,987,277	305,249,824
Preferred Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Preferred Units	407,955,726	257,000,129
Management Incentive Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Preferred Units	72,801,666	45,678,102
Unvested Common Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Preferred Units	1,229,885	2,571,593